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SUMMARY
The ch aracter is tics  of the chemical compounds known as the 
cardiac glycosides are reviewed, with p a r t ic u la r  reference to the 
d ig i t a l is  group. The c l in ic a l  use of d ig i t a l is  is outlined from 
i t s  orig ins in fo lk  medicine to the present day. I t  is  pointed 
out tha t d ig i t a l is  is in common use in the treatment of heart 
disease but the ra t io  is small between the dosage which produces 
the desired c l in ic a l  e f fe c t  and th a t which causes to x ic i ty .  The 
pharmacokinetics of the most commonly used cardiac glycoside,digoxin , 
are summarised, Digoxin was one of the f i r s t  preparations formulated 
with the use of the mass-production ta b le t t in g  process and the 
features of th is  type of formulation are described. The concepts 
of b io a v a i la b i l i ty  o f drug formulations and i t s  methods of measurement 
are discussed and the progress of awareness of i ts  c l in ic a l  relevance 
is reviewed,
A description is given o f how d i f f i c u l t y  in achieving f u l l  
d ig i ta l is a t io n  in a pa tien t suffering  from paroxysms of a t r ia l  
f i b r i l l a t i o n  led to the re a l is a t io n  that absorption of digoxin in 
that patien t was impaired. Changing the brand of digoxin ta b le t  used 
by th is  pa tien t to Lanoxin gave more rapid absorption and higher steady 
state  plasma digoxin concentrations. When the pa tien ts ' o r ig in a l  
tab le ts  were ground to a f in e  powder and administered w ith in  a capsule 
there were fu r th e r  increases in absorption rate  and steady state  
concentrations. S im ila r  resu lts  were found in a second p a tien t.  
However, in a fu r th e r  group of 5 patients with low plasma digoxin 
concentrations or inadequate control of a t r ia l  f i b r i l l a t i o n  no 
s ig n if ic a n t  r ise  in plasma digoxin concentrations were seen a f te r
changing to Lanoxin. The plasma digoxin concentrations in a survey 
of out-patients  using Lanoxin and a va r ie ty  o f other brands were 
lower than those reported a few years e a r l ie r  in s im ila r  patients  
on equivalent digoxin doses. An explanation of those findings was 
not apparent u n ti l  the Burroughs Wellcome Company, manufacturers of 
Lanoxin, revealed that medications in the production process of  
Lanoxin were thought to have pronounced effects  on b io a v a i la b i l i t y .  In 1972 
they announced, th a t a change in production technique a few weeks e a r l ie r  
had doubled the b io a v a i la b i l i t y  o f Lanoxin. I t  became known th a t an 
e a r l ie r  change in 1969 had probably halved Lanoxin b io a v a i la b i l i t y .
The results in the ou t-p a tien ts ' survey supported th is  view of the 
e f fe c t  o f  the 1969 change and suggested that major differences in  
b io a v a i la b i l i ty  again existed between Lanoxin and many other brands 
of digoxin ta b le t .
A comparison of 'newer Lanoxin' made since the most recent 
production change and 'o lder  Lanoxin' manufactured ju s t  before th is  
change confirmed tha t newer Lanoxin gave higher steady state  plasma 
digoxin concentrations and absorption was more rapid. The mean 
increase in b io a v a i la b i l i ty  was 70%, but indiv idual patients showed 
marked va r ia t io n  in t h e i r  response to a change in form ulation, with  
some showing severa l-fo ld  increases in digoxin concentration. Newer 
Lanoxin had a much fa s te r  in v i t r o  d issolution rate  than older 
Lanoxin, although both had d is in teg ra tio n  rates w ith in  the l im its  
stipu la ted  by the B r it is h  Pharmacopoeia. Measurement o f the 
dissolution rate  of 15 other brands of digoxin ta b le t  marketed in the 
United Kingdom showed a wide d is tr ib u t io n  of values.
A t r i a l  to compare the b io a v a i la b i l i ty  and c l in ic a l  e ff icacy  
of 7 digoxin brands was carried  out in 2 groups of cardiac p a tien ts .
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using steady state  plasma digoxin concentration as the measure of 
b io a v a i la b i l i ty .  This confirmed the difference between older and 
newer Lanoxin and showed th a t the b io a v a i la b i l i ty  of the other 
brands ranged from a b io a v a i la b i l i ty  s im ila r  to older Lanoxin to a 
b io a v a i la b i l i ty  almost equal to the newer Lanoxin, The differences  
in plasma digoxin concentration were associated with s ig n if ic a n t  
differences in the v e n tr ic u la r  rate  o f those patients who had a t r ia l  
f i b r i l l a t i o n .  There was a close corre la tion  between b io a v a i la b i l i ty  
of these brands and in v i t r o  dissolution rate: there was a corre la tion  
c o e ff ic ie n t  o f 0 . 8 8  between mean steady state  plasma digoxin 
concentration and the percentage of the dose in solution at 30 minutes.
The p ro f i le  of the re la tionsh ip  between d issolution rate  
and b io a v a i la b i l i ty  suggested that there might be an upper l im i t  of 
dissolution ra te  beyond which no fu rth e r  increase in digoxin absorption 
would occur. A study was made of newer Lanoxin and 4 formulations designed 
to provide very rapid in v i t r o  d isso lution . Absorption curves showed 
that these formulations were a l l  rap id ly  absorbed. When administered 
in random order to a group of cardiac out-patients no differences were 
found in steady state  plasma digoxin concentrations. This suggested 
th a t a lower l im i t  o f dissolution ra te  of at le as t 70% in solution at 
30 minutes would help to ensure consistent equivalence of b io a v a i la b i l i ty  
of digoxin ta b le ts . The B r it is h  Pharmacopoeia la te r  came to introduce 
a new requirement th a t digoxin tab le ts  have a dissolution rate  of at  
least 80% in solution a t 1 hour.
To investigate  the cause of the differences which had existed in  
digoxin ta b le t  b io a v a i la b i l i ty  the e f fe c t  o f digoxin p a r t ic le  size was 
examined. The digoxin powders used fo r  digoxin ta b le t  manufacture were
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found to have a log-normal d is tr ib u t io n  and 50% oversize values from 
22 to 29pm. One such powder was mill-ground to produce powders of  
12 and 3.7pm sizes. The smaller p a r t ic le  size led to more rapid  
absorption when these powders were administered w ith in  cachets and 
steady state  plasma digoxin concentrations rose as p a r t ic le  size  
decreased. I t  was concluded th a t changes in p a r t ic le  size during 
ta b le t  manufacture would cause a lte ra t io n s  in digoxin b io a v a i la b i l i ty ,
I z
CHAPTER 1 
REVIEW
THE CARDIAC GLYCOSIDES
There is in nature a group o f  substances which share a basic 
stero id-lactone structure and a p a r t ic u la r  action on the heart. They 
are called the cardiac glycosides. Over 300 natura lly -occurring  or 
semi-synthetic cardiac glycosides e x is t  (Smith and Haber, 1973).
The d ig i t a l is  plant is the most important source o f these substances 
and the term d ig i t a l is  is often used fo r  the group as a whole. D ig i ta l is  
purpurea, the purple foxglove, is native to B r i ta in .  I t  provides three 
major cardiac glycosides - d ig ito x in ,  g itox in  and g i ta l in  (Moe and Mafah, 
1970). D ig i ta l is  lanata , the white foxglove, is native to Eastern 
Europe and also contains d ig ito x in  and g itox in  but has digoxin as a 
th ird  main constituent. The name d ig i t a l is  was given to the plant by 
Fuchs (1542) when he provided i ts  f i r s t  botanical description : i t  is  
the Latin equivalent of i t s  German name 'F in g erh u t ',  meaning f in g e rs ta l l  
or thimble,
A c h arac te r is tic  action o f d ig i t a l is  on the frog heart was 
demonstrated by Vulpian (1855). This type of a c t iv i ty  and a s te ro id -  
lactone structure were found to be possessed by substances in many 
d if fe r e n t  plants. Cushny (1925) l is te d  18 other species of plant known 
to have cardiac glycosides and Weese (1936) l is te d  30 sources. These 
include such disparate orig ins as l i l y  of the v a l le y ,  s q u i l l ,  toad skin 
and arrow poison preparations from A frica .
A ll o f the cardiac glycosides have the same actions on the 
human heart. They increase the farce and ve lo c ity  o f myocardial
I o
contraction and they a l t e r  in a ch arac te r is t ic  way the 
electrophysiological s tate  o f the heart. The electrophysiological 
effects  are complex and encompass changes in pacemaker autom atic ity , 
e x c i t a b i l i t y ,  membrane responsiveness, conduction v e lo c it ies  and 
re frac tory  periods, with each e f fe c t  d i f fe r in g  according to the 
c e l lu la r  structure involved (Smith and Haber, 1973). A huge amount of  
experimental evidence has accumulated about the mechanisms by which the 
cardiac glycosides exert these e ffe c ts . Schatzman (1953) showed that  
d ig i t a l is  had a d ire c t  e f fe c t  on cation transport across the membrane 
o f the erythrocyte. Na*, -ATPase was found to be a membrane-bound 
cation transport enzyme (Skou, 1957) and Repke (1963) postulated that  
th is  enzyme system was the receptor fo r  the cardiac glycosides. I t  is 
now generally accepted tha t the electrophysiological e ffects  of a l l  
cardiac glycosides are due to changes in membrane potentia l a r is ing  
from in h ib it io n  o f Na^, -ATPase and there is considerable but not 
conclusive evidence that the e f fe c t  on contraction has the same basis 
(Hayward and Hamer, 1979; Smith and Braunwald 1980). A hypothesis to 
f i l l  the gap between a change in Na*, -ATPase a c t iv i ty  and a change 
in the actin-myosin contraction process has been developed by Langer 
(1968) and Akera and Brody (1977). They suggest that an increase in 
in t r a c e l lu la r  Na  ^ resu lting  from Na^, -ATPase in h ib it io n  produces 
an enhanced in f lu x  of calcium ion v ia  the sodium-calcium exchange 
c a rr ie r  mechanism. The increase in calcium ion augments c o n tra c t i le  
element coupling. An explanation of events beyond th is  step is  
in h ib ited  by lack of knowledge about the co n tra c tile  process i t s e l f .
The c l in ic a l  usefulness of the cardiac glycosides is lim ited  
by the development of to x ic i ty  as dosage increases. Tox ic ity  may be 
manifest by arrhythmias, nausea and vomiting or disturbance of vision
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or mental s tate: the development of to x ic i ty  is due to the 
electrophysiological a lte ra t io n s  w ith in  the heart (Mason and 
Foerster, 1981) and to d ire c t  central nervous system effects  
(Benthe, 1981). In the United Kingdom d ig i t a l is  to x ic i ty  is said 
to occur in between 13% and 20% of hospital patients receiving a 
cardiac glycoside (Hurwitz and Wade, 1969; Curruthers, Kelly and 
McDevitt, 1974). There have now been 34 studies comparing plasma 
digoxin concentrations in tox ic  and non-toxic p a tien ts , and 12 studies 
comparing plasma d ig ito x in  concentrations (Smith and Braunwald, 1980). 
The great m ajority  of these studies show that the cardiac glycoside 
concentration in the blood was usually 2 - 3  times higher in toxic  
patients . However there is a degree of overlap between the levels  
found in toxic  and non-toxic pa tien ts . These studies re-emphasised 
the narrow tox ic -therapeutic  ra t io  which c lin ic ia n s  have long recognised 
to e x is t with the cardiac glycosides.
Chemical analysis of the cardiac glycosides revealed the four  
molecular characteris tics  which are necessary fo r  potent cardio a c t iv i ty  
(Henderson, 1969): they are (1) an unsaturated lactone ring at the C17 
position o f the stero id  nucleus (2) a hydroxyl group at Cl4 (3 ) a cis 
stereochemical arrangement at Cl3 -  14 (4) one or more sugars at C3.
I t  is digoxin which has become the most commonly used cardiac 
glycoside although d ig ito x in  is favoured in French-speaking countries 
and a number of other plant sources are s t i l l  used in Russian medicine.
CLINICAL USE OF DIGITALIS 
The d ig i t a l is  plant is  one o f the most ancient medicines s t i l l  
employed today. The f i r s t  pharmacopoeia of the Royal College of  
Physicians in Edinburgh, published in 1699, included d ig i t a l is  purpurea.
I t  was among the l i s t  of 'simples' i . e .  substances of d ire c t  p lan t,  
animal or mineral o r ig in  which were in therapeutic use. At that time 
the boundary between fo lk  remedies and the medicines used by physicians 
was in d is t in c t  and many of these simples owed t h e i r  place to th e ir  
reputation in fo lk lo re  - for example, cranium hominis v io len ta  morte 
e x t in c t i  was also l is te d  among the simples.
In the 17th century d ig i t a l is  was taken fo r  epilepsy and 
phthisis or applied ex tern a lly  fo r  wounds, u lcers, scofula and caries  
(Parkinson 1640, W ithering, 1785). Application to the skin was used 
presumably because o f the local i r r i t a n t  action which can be followed 
by a numbness (Cushny, 1925), However Parkinson (1640) t e l ls  us that  
"there are but few Physitions (s ic )  in our times that put i t  to these 
uses but i t  is in a manner wholly neglected".
Many of the simples l is te d  in the 1699 Edinburgh Pharmacopoeia 
were removed from subsequent ed it ions . D ig i ta l is  was dropped from the 
5th ed ition  o f 1756. The foreword explained tha t the Pharmacopoeia 
had banished many simples which had been previously included only because 
of "supers tit ion" , "credulity"  or "established custom". Also, Salerene 
(1748) had published his experiments showing severe toxic  e ffects  from 
d ig i t a l is  in turkeys ( th is  was one of the f i r s t  animal experiments in 
pharmacology).
In 1775 William Withering was asked fo r  his opinion on a herbal 
recipe with which a Shropshire woman, Mrs Hutton, had cured a case of 
dropsy a f te r  the e ffo r ts  o f physicians had fa i le d .  There were over 
20 ingredients in her recipe but W ithering's knowledge of botany 
allowed him to id e n t ify  foxglove as the l i k e ly  active ingredient.
He began to use the foxglove himself and to observe i ts  effects  
in patients who attended his busy d a ily  c l in ic s .  His Treatise  of
1785 describes his results in 163 of his own cases and in 46 cases 
reported to him by colleagues. He found that d ig i t a l is  could produce 
a diuresis in cases of dropsy and that i t  was more potent in these 
cases than any other medicine then av a ila b le . He also concluded 
"that i t  has a power over the motion of the heart, to a degree yet 
unobserved in any other medicine, and that this power may be converted 
to sa lutary ends".
Withering^s care and thoughtfulness as an investigato r is shown 
not only by his shrewd conclusions about the c l in ic a l  e ffects  of 
d ig i t a l is  but by the way in which he sought the best formulation and 
dosage of the drug. He preferred the use of the leaves, with s ta lk  
and midrib removed, collected at the time of flowering in the p lan t's  
second year. These leaves he rubbed into powders and they were 
dispensed as such or made in to an e l i x i r  or in fusion , o r , added to soap 
or gum ammoniac, in to  a simple p i l l .  However, he cautioned that  
"the more we m ultip ly  the forms of any medicine, the longer we shall 
be in ascertaining i ts  real dose".
At f i r s t  he used dosages which were large and frequent and 
rap id ly  provoked to x ic i ty .  As his experience o f the plant grew his 
concept o f  the proper method o f dosage improved. He noticed that the 
increased flow of urine preceded evidence of to x ic i ty .  Smaller doses 
produced a period of benefic ia l e f fe c t  before any to x ic i ty  supervened. 
He advised that dosing could be stopped for an in te r v a l ,  without losing  
the b e n e f it ,  as soon as signs o f to x ic i ty  appeared. His eminently 
practical recommendation was:- "Let the medicine therefore be given in  
the doses and at the in terva ls  mentioned above: le t  i t  be continued 
u n ti l  i t  e ith e r  acts on the kidneys, the stomach, the pulse, or the 
bowels; l e t  i t  be stopped upon the f i r s t  appearance o f any of these
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e f fe c ts ,  and I w i l l  maintain tha t the pa tien t w i l l  not su ffe r  from 
i t s  e x h ib it io n , nor the p ra c t it io n e r  be disappointed in any reasonable 
expectation".
I t  is in te re s tin g  to look a t the doses he suggested. The main 
emphasis is on a dose o f 1 -  3 grains of powdered le a f  twice a day
i . e .  approximately 60 -  180mg B.D. The present recommended d a ily  
maintenance dose o f prepared d ig i t a l is  le a f  BP is 100 -  200mg per day 
(Smith, 1973). With W ithering's o r ig in a l regime one would expect to 
find to x ic i ty  in about 1 -  3 weeks. However by the year o f the 
publication o f his monograph, some 10 years a f te r  his f i r s t  use of  
d i g i t a l i s ,  he became "disposed to believe that the d ig i t a l is  may be 
given in small doses, v iz  2 -  3 grains per day, so as gradually to 
remove a dropsy, without any other than mild d iu re t ic  e f fe c ts ,  and 
without any in terrup tion  to i t s  use u n ti l  the cure be completed". 
Withering had reached the concept o f avoiding to x ic i ty  e n t i re ly .  However 
th is  point was not taken up by his contemporaries who would normally 
continue d ig i ta l is a t io n  to the point o f to x ic i ty .  For some people 
d ig i ta l is  developed a reputation o f being a dangerous medicine capable 
of causing sudden death. Dr John Lettsom, then one of London's 
most emminent physicians, said he had seen eight f a t a l i t i e s  during 
d ig i ta l is a t io n .  Withering replied that this was the re su lt  of excessive 
dosage used for inappropriate patients (Foy, 1915).
The obvious e ff icacy  of d ig i t a l is  ensured i ts  popularity . The 
Edinburgh New Dispensatory (1789) began i ts  section on d ig i t a l is  with a 
r e i te ra t io n  o f the old uses but added " D ig i ta l is ,  however, has la te ly  
been employed with great success in other diseases. A t re a t is e  has 
recently  been published by Dr Withering . . .  containing many important 
and useful observations". William Cullen (1789) in his Treatise  on the
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Materia Medica advised th a t W ithering's monograph "should be in the 
hands of every p ra c t it io n e r  o f physic".
The causes of dropsy were a t  th is  time not well understood and 
although Withering had mentioned the p a r t ic u la r  e f fe c t  of d ig i t a l is  
on the heart the p lant was i n i t i a l l y  used as general d iu re t ic .  Cullen 
(1789) wrote: "The powers o f  th is  p lant as a d iu re t ic  are now ascertained  
by numberless experiments: but upon what sort of operation these powers 
depend I am at a loss to explain".
Physicians came gradually to re a l is e  that d ig i t a l is  was e f fe c t iv e  
when dropsy was caused by heart disease. They were however puzzled 
by the apparent paradox of the slowing e f fe c t  on pulse rate  -  a 'sedative'  
e f fe c t  -  and the more positive  action of producing diuresis -  a 's tim ulant' 
e f fe c t .  A long and sometimes acrimonious debate developed as to which of  
these e ffects  was the more important. F err ia r  (1799) was the f i r s t  to 
emphasise d ig i t a l i s '  e f fe c t  on the heart but propounded the sedative  
point of view, with some force , when he wrote " I f  I am acquainted with an 
undubitable fa c t  in medical p rac tic e , i t  is the power of d ig i t a l is  in 
retarding and weakening the action o f the heart and a r te r ie s " .
Bouillard (1835), able to use the new technique of auscultation, described 
the marked slowing of the heart which d ig i t a l is  could produce in cases 
with a rapid ir re g u la r  pulse, and called d ig i ta l is  "the opium of the heart"
The controversy was s t i l l  intense in 1869 when, at a meeting of  
the Medico-Chirurgical Society of Edinburgh, Bennett clashed with  
Balfour (1870): Bennett said he was "aware that a modern idea was a f lo a t  
that d ig i t a l is  was a stimulant to the heart: th is  he conceived to be 
erroneous. He held to the ancient b e l ie f  that d ig i t a l is  was a pure 
sedative to the heart's  action'*. George Balfour, who had carried out anima' 
experiments as well as practic ing as a c l in ic ia n ,  disagreed and pointed
out th a t the pulse could sometimes be f e l t  to strengthen before there  
was any dimination of i ts  frequency. Fo therg ill  (1871), in a lecture
on d i g i t a l i s ,  stated that d ig i t a l is  was " ..........  a drug whose action
was unquestionably to produce b e tte r ,  more complete v e n tr ic u la r  
contraction and in th a t ,  and that only , I believe the magic l ie s " .
The a r r iv a l  of polygraph recordings of a t r ia l  and v e n tr ic u la r  
action demonstrated the nature of a t r ia l  f i b r i l l a t i o n  (Mackenzie, 1905) 
and showed that d ig i t a l is  increased a tr io -v e n tr ic u la r  block. S i r  James 
Mackenzie (1914) concluded tha t " i t  is in the treatment of au ricu lar  
f i b r i l l a t i o n  that we find the great value of th is  drug". However 
he had also been able to record marked improvement from heart fa i lu r e  
in  a patient with complete a t r io -v e n tr ic u la r  block in whom d ig i ta l is a t io n  
did not reduce the heart ra te  (Mackenzie, 1911). Several c l in ic ia n s ,  
such as Christian (1919) o f Boston, reported substantial improvement 
a f te r  d ig i ta l is a t io n  of patients in sinus rhythm. Nevertheless 
B rit is h  views were very influenced by S ir  Thomas Lewis who held that  
the benefit of d ig i t a l is  lay in extending the d ia s to l ic  period 
(McMichael 1972). A crucia l stage was reached when C atte l l  and Gold 
(1938) showed that cardiac glycosides increased the force and v e lo c ity  
o f contraction o f iso lated p a p il la ry  muscle. The demonstration of 
increased c o n t r a c t i l i ty  in patients awaited the introduction o f  
cardiac ca theterisa tion  and cardiac surgery since there was then no 
adequate animal model for heart f a i lu r e .  McMichael and Sharpey-Shafer 
(1944) showed that a f te r  d ig i ta l is a t io n  patients with heart fa i lu r e  had 
a r is e  in both cardiac output and a o rt ic  pressure while f i l l i n g  pressure 
was reduced. Increased v e n tr icu la r  contraction in the n o n -fa i l in g  
heart was demonstrated by Braunwald et a l . ,  (1961) using s tra in  gauges 
attached to the v e n tr ic u la r  wall at the time of cardiac surgery. S im ila r
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effects  were confirmed in the conscious patient at cardiac  
catheterisa tion  (Mason and Braunwald, 1963, Yankopoulos et a l . ,  196&) 
and by non-invasive techniques (Weiss 1er e t a l . ,  1965).
In addition to i t s  main e ffec ts  on a t r io -v e n tr ic u la r  conduction 
and myocardial contraction, d ig i t a l is  has other actions on the 
c irc u la t io n . I t  influences vagal and sympathetic tone, peripheral 
vascular resistance and renal blood flow. I t  also has non-cardiac 
effects  on the g a s tro -in te s tin a l t r a c t ,  adipose t issue , central nervous 
system and sex hormones (Hayward and Hamer 1979). The important 
actions however l i e  in the effects  on conduction and contraction -  the 
modern equivalents o f the old 'sedative ' and 's tim ulant' e ffects  -  and 
these form the basis to i ts  current employment in the control of  
supraventricular arrhythmias and the treatment of heart fa i lu r e  due 
to myocardial impairment (Smith and Braunwald 1980, Grosse-Brockhoff 
and Peters 1981). Controversy has not subsided. Some believe there  
is no long-term benefit  from d ig i t a l is  fo r  patients who are in sinus 
rhythm and receiving treatment with d iu re tics  (P la t t  1975, Lancet 1976) 
Hamer (1979) reviewed the evidence on th is  point and concluded tha t  
at leas t some patients with sinus rhythm did derive long-term benefit  
from d ig i ta l is a t io n  but i f  no improvement was d iscern ib le , or i f  
d ig i ta l is a t io n  proved d i f f i c u l t ,  then a t r i a l  period without d ig i t a l is  
was c e rta in ly  ju s t i f ie d .  A recent important haemodynamic study 
(Arnold e t  a l . ,  1980) showed a substantial and sustained benefit  at 
rest and on exercise in patients with severe myocardial disease who 
were in sinus rhythm and already receiving d iu re t ic  therapy.
DTGOXIN
The chemical content of plants can vary from year to year and 
from region to region, as demonstrated by the vine. Withering tr ie d
to overcome v a r ia t io n  in the content o f the active substances in the 
foxglove by se lecting only parts o f the plant fo r use and by gathering  
them at a specified season. The powder of Prepared D ig i ta l is  used 
today can be standardised by bio logical assay using fro g , cat or 
pigeon preparations but these methods are imprecise (Stewart, 1981). 
Attempts to obtain a chemically pure cardiac glycoside began with  
Hemolle and Quevenue (1844) who extracted a more active  princip le  -  
amorphous d ig i ta l in e  -  from the purple foxglove. However i t  was only 
a f te r  N a tiv e l le  (1869) extracted c ry s ta l l in e  d ig i ta l in e  with  
chloroform that p u rif ied  glycosides began to be used c l in ic a l ly .  
D if f ic u l t ie s  with the extraction process seem to have been persistent  
and Dick (1948) detected differences in the control of a t r ia l  
f i b r i l l a t i o n  when a v a r ie ty  o f commercial d ig i ta l in e  preparations 
were used by the same group o f patien ts . The purity  of d ig ito x in  
powder (as the d ig i ta l in e  ex trac t came to be ca lled ) remains less 
demanding than that o f  digoxin powder (B rit ish  Pharmacopoeia, 1968).
Digoxin was iso lated from d ig i t a l is  lanata by Smith (1930) who 
worked in the laboratories of Burroughs Wellcome Ltd. In i ts  
c ry s ta l l in e  form digoxin is  a w hite , odourless substance with a b i t t e r  
tas te . I t  is very poorly soluble in water and soluble 1 in 122 in 80% 
alcohol. The molecular weight is  781. I t  has a five-membered lactone 
r in g , three sugar molecules attached at the C3 position o f the steroid  
nucleus and d i f fe rs  from d ig ito x in  by having a hydroxyl group at Cl2 
(B r i t is h  Pharmacopoeia, 1968).
I ts  c l in ic a l  pharmacology was f i r s t  investigated by Wayne (1933) 
who compared oral and intravenous doses and concluded that a solution  
o f  digoxin was " fa i r l y  completely" absorbed when taken o ra l ly .  An 
oral dose o f  1.5mg produced much the same e f fe c t  as I.Omg intravenously.
The e f fe c t  o f digoxin on a t r ia l  f i b r i l l a t i o n  was seen to be more 
rap id ly  dissipated than the e f fe c t  of d ig ito x in  or d ig i t a l is  le a f .
He suggested tha t the average dosage o f digoxin should be 0.5mg/day.
S im ilar work was carried  out by Rose, Batterman and deGraaf 
(1942) and by Evans, Dick and Evans (1948).
Gold e t a l . ,  (1953) carried out fu r th e r  d e ta iled  studies on 
the c l in ic a l  e ffects  of digoxin in the 1940's . They also observed 
the e ffects  of oral and intravenous doses in patients who had a t r ia l  
f i b r i l l a t i o n  with rapid v e n tr ic u la r  ra tes . From the changes in heart 
rate  they estimated tha t about two th irds of an oral digoxin dose was 
absorbed whereas absorption o f d ig ito x in  appeared complete. They 
drew atten tion  to the d ifferences in the doses of oral digoxin needed 
fo r  d ig i ta l is a t io n  in th e ir  studies and in those reported by the 
previous workers. They raised the question as to whether th is  might 
r e f le c t  differences in the digoxin preparations used.
At th is  time there was no assay method s u f f ic ie n t ly  sensitive  
to measure the amounts of digoxin present in the body f lu id s .  The 
calculation of physiological concentrations of digoxin became possible  
with the advent o f radio-isotopes. A fte r  administration of H^-labelled  
digoxin, Doherty, Perkins and M itchell (1961) were able to estimate 
the amounts o f digoxin in plasma, urine and faeces. , In a series of 
studies with radioactive d igoxin , Doherty and his colleagues defined 
the pattern and k inetics  of digoxin 's absorption, d is t r ib u t io n ,  
excretion and metabolism. This work has been summarised by Doherty 
(1968). His group concluded tha t a f te r  an intravenous dose digoxin 
was rapidly  d is tr ibu ted  to the tissues where there was a high degree o f  
protein binding. A large proportion of the dose was excreted in to  the 
urine mainly in unchanged form. The rate of excretion was very
dependent on the state  of renal function, and digoxin clearance 
p a ra lle l le d  creatin ine  clearance and had an inverse l in e a r  
re la tionsh ip  to blood urea concentration. When renal function was 
normal, the h a l f - l i f e  o f e lim ination was approximately 1|  days but 
h a l f - l i f e  was extended to 7 days in anephric patients . An oral 
dose of digoxin solution was estimated to be about 80% absorbed.
Their  data showed that there were considerable differences in the 
pharmacokinetic p ro f i le  of d i f fe r e n t  subjects.
The ra d io a c t iv ity  of these isotopes prevented them being prepared 
as normal ta b le t  formulations or being used for long-term adm inistration. 
During the 1960‘ s , a v a r ie ty  of d i f fe re n t  assays fo r plasma concentrations 
o f digoxin became ava ilab le  (B u tle r , 1972). Two types o f assay became 
popular as they combined adequate s e n s it iv i ty ,  accuracy and s p e c if ic i ty  
with r e la t iv e ly  rapid and simple technique. One was the radioimmunoassay 
developed by Smith, Butler and Haber (1969) a f te r  Butler and Chen (1967) 
had succeeded in ra is ing h ig h -a f f in i ty  antibody to digoxin in rabbits .
The other was based on the measurement o f in h ib it io n  of uptake o f  
rubidium^^ by erythrocytes. This type of assay was f i r s t  introduced 
by Lowenstein (1965), and la te r  improved by Lowenstein and C o rr i l l  (1966), 
B ertle r  and Redfors (1970), and Gjerdun (1970).
The application of the newer assays has la rge ly  confirmed 
Doherty's conclusions about the main pharmacokinetic parameters. An 
exception is the pattern o f excretion - i t  is now known that digoxin 
undergoes a greater degree of metabolism than Doherty and colleagues 
had thought. Also work in the 1970's, some with the newer assays 
and some with radioisotopes, has added greater d e ta il  to the 
pharmacokinetic knowledge. A fte r  an intravenous bolus dose there is  
a phase lasting a few minutes in which the digoxin is d ilu ted in the
blood stream. There follows a d is tr ib u t io n  phase with a h a l f - l i f e  
of ju s t  over 0.5 hours: a f te r  a few hours the terminal e lim ination  
phase begins, with a h a l f - l i f e  o f 26 -  44 hours in normal subjects 
(Greenblatt et a l , ,  1973, Nyberg, Anderson and B e r t le r ,  1974a,
Kramer et a l . ,  1974, Koup e t a l . ,  1975). This phase is extended 
to over 100 hours in patients with marked renal impairment (Reuning,
Sams and N o ta r i , 1973, Ohnhaus, Spring and D e t t l i ,  1974). In normal 
subjects between 57% and 80% of the intravenous dose has appeared 
in the urine in various studies. Renal excretion appears to involve  
not only f i l t r a t i o n  at the glomerulus but also tubular secretion  
and reabsorption (Steiness 1974, Doherty, Ferre ll  and Towbin 1969).
The digoxin molecule may undergo three types o f metabolic change 
-  removal o f the sugar molecules, conjugation with glucuronate and 
sulphate ra d ic a ls , and saturation o f  the lactone ring (Reitbrock and 
Woodcock 1981). These metabolic processes influence the d ig i t a l is  
e ffe c t  by several mechanisms. Some of the metabolites lose th e ir  
c a rd io a c t iv ity ,  although others have s im ila r  potency to digoxin. The 
l ip id  s o lu b i l i ty  of the metabolic products is  often d i f fe re n t  to that  
of digoxin and th is  change w i l l  a l t e r  the a b i l i t y  to cross l ip id  
membranes. The e lim ination rate  is also changed: the h a l f - l i f e  of 
digoxigenin monodigitoxoside is h a lf  th a t  of digoxin. P a rt ic u la r  
in te re s t  has been paid to the inactive  dihydro compounds in which the 
lactone ring has become saturated. These are found in the urine  
a f te r  an intravenous dose (Lindenbaum et a l . ,  1981a) but occur in 
much higher amounts a f te r  oral doses. Clark and Kalman (1974) found 
tha t o f  50 patients taking regular digoxin doses 48 excreted a 
detectable (more than Ing/ml) amount o f  dihydrodigoxin, which ranged 
from 1 to 47% of the to ta l extractab le  glycoside in the urine. The mean
urine level o f dihydrodigoxin was 13%. Greenwood e t a l . ,  (1975) noted 
in nine patients that 16.4% (range 12.2% -  19.7%) of the to ta l oral 
dose was excreted in the urine as dihydrodigoxin. The proportion 
of to ta l  glycoside present as metabolites has tended to be greatest  
in the faeces, with lesser proportions in the urine and p a r t ic u la r ly  
in  the plasma. However Watson et a l . ,  (1973) when measuring plasma 
digoxin concentration by gas chromatography detected an abnormal peak 
in 3 o f 150 patients and showed tha t th is  peak represented dihydrodigoxin. 
In one o f these cases the plasma dihydrodigoxin concentration was 30% 
tha t of digoxin. Lindenbaum et a l . ,  (1981b) reviewed the urinary output 
o f reduced digoxin derivatives  of 131 normal subjects who had taken part 
in b io a v a i la b i l i ty  studies. Ten per cent of these subjects showed 
marked conversion to dihydro forms (greater than 40% of urinary glycoside). 
They noted that slowly dissolving formulations of digoxin were 
associated with greater conversion to these metabolites and they 
suspected that the in te s t in a l bacteria  played an important part in  the 
metabolic conversion. The a b i l i t y  of in te s t in a l bacteria  to convert 
digoxin to dihydrodigoxin had been demonstrated e a r l ie r  in v i t r o  by 
Herrmann and Repke (1968). Lindenbaum et a l . ,  (1981b) subsequently 
showed that a course o f a n t ib io t ic s  caused a marked drop in the 
excretion of the reduced metabolites. Serum digoxin concentration 
rose by up to two-fold a f te r  a n t ib io t ic  administration. The influence  
of the in te s t in a l f lo ra  may therefore explain some o f the differences  
in  absorption between indiv iduals  using the same digoxin formulation.
In v i t ro  incubation has shown that gastric  acid can cleave the 
sugar components from the digoxin molecule (Beermann, Hellstrom and 
Rosen 1972; Gault e t a l . ,  1977). The magnitude of th is  change is 
proportional to the pH and to the duration of exposure to the acid.
The extent to which th is  occurs in  vivo has not been quantified but 
the in v i t ro  data suggests th a t the e f fe c t  is very small when pH 
is w ith in  the normal range.
Within the in te s t in e s , digoxin is  rap id ly  absorbed in the upper 
portions (Beerman e t a l . ,  1972). Absorption of doses placed w ith in  
the colon has been found to be surpris ing ly  extensive, although 
delayed (Ochs et a l . ,  1975, Anderson et a l . ,  1975).
Gastrointestinal t ra n s i t  time was shown to have an influence on 
the absorption from slowly dissolving digoxin tab lets  by Manninen 
e t a l . ,  (1973a), who modified in te s t in a l  m o t i l i ty  with propantheline  
and metoclopramide. However no s ig n if ic a n t  change occurred when rap id ly  
dissolving tab le ts  were used (Manninen et a l . ,  1973b).
The presence of overt in te s t in a l  disease has reduced digoxin 
absorption in some studies (H eizer, Smith and Goldfinger (1971),
Jusko e t  a l . ,  (1974), Brachtel and G i l f r ic h  (1977), Kolibash et a l . ,
(1977)) but not in others (Hall and Doherty, (1974), Marcus et a l . ,  (1977)) .
The to ta l absorption of an oral solution of a cardiac glycoside 
varies from minimal to complete and is dependent mainly on the degree 
of l ip o p h i l ia  of the p a r t ic u la r  glycoside molecule (Lauterbach 1981). 
Absorption of a digoxin solution is incomplete: d i f fe re n t  studies have 
yielded d i f fe re n t  percentage figures but on average only about three  
quarters of an oral dose is absorbed (Shaw, 1977). There is v a ria t io n  in 
extent of absorption of ju s t  over two-fold in normal subjects, with  
each subject tending to be consistent (Johnson, Bye and Lader 1974).
In a fasting  subject the peak plasma digoxin concentration  
occurs at 1 hour: a recent meal reduces the rate of absorption but 
not i ts  extent (White et a l . ,  1971, Sanchez- et a l . ,  1973). Analysis 
o f  d ie ta ry  h isto ries  suggested that f a t  consumption had a very minor
e ffe c t  on digoxin absorption (Turner et a l . ,  1977). Brown et a l . ,
(1978) estimated that a high f ib re  content meal reduced absorption 
by 18%.
A large number of reports have accumulated to l in k  reduction  
of digoxin absorption and co-administration of other drugs 
(Shaw 1981, Manninen and Nyberg 1981). The drugs involved have been 
neomycin, sulphasalazine, diphenylhydantoin, para-am inosalicylic  
acid, various antacids, K ao lin -pectin , cholestyramine and c o le s t ip o l,  
and activated charcoal. Spironolactone reduces the clearance of 
digoxin by a quarter while frusemide causes a mild tran s ien t increase. 
An in terac tion  o f  greater magnitude has been shown to occur with 
quinidine. Ejvinsson (1978) f i r s t  reported than an increase in plasma 
digoxin concentration was induced by quinidine. Others have confirmed 
th is  observation and have shown that the increase, which is on average 
ju s t  under 100%, can induce d ig i ta l is  to x ic i ty  (Manninen et a l . ,  1981). 
There have been more recent suggestions that verapamil and amiodarone 
also a l te r  plasma digoxin concentration but the magnitude and 
significance of these possible in teractions  has not yet been c la r i f ie d .
Fortunately digoxin is not strongly bound to plasma proteins and 
is  not vulnerable to displacement by other drugs (Wallace and Whiting, 
1974). The low level of hepatic metabolism renders i t  free from 
in terference by induction of l i v e r  enzyme a c t iv i ty .
The picture which has emerged from these more recent studies is 
one o f a complex pattern of absorption, excretion and metabolism, with  
many factors influencing the steady state  plasma digoxin concentration 
achieved by a p a r t ic u la r  dose and with considerable v aria t io n  between 
in d iv id ua ls . The measurement of the steady state  plasma digoxin 
concentration can be useful in assessing d ig i ta l is a t io n  as the steady
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state  level is the accumulated resu lt  of the many co n fl ic t in g  
influences on digoxin pharmacokinetics in an ind iv idua l.
TABLETTING
When digoxin began to be marketed by Burrough Wellcome Ltd 
in the 1930's i ts  a ttra c t io n  lay in the fac t  that i t  was a chemically 
pure substance and doses could be standardised by weight alone.
At the time digoxin was f i r s t  marketed tablets  were beginning 
to be produced on a mass scale using automated ta b le t t in g  machines. 
Burroughs Wellcome themselves designed and constructed th e ir  f i r s t  
ta b le t t in g  equipment and marketed th e ir  new digoxin under the brand 
name 'Tab lo id*. Later the brand name was changed to 'Lanoxin'.
A ta b le t  is defined as "a un it dosage form o f  medication
containing one or more drugs to which excipients may have been added
and compressed as granules in powder to a d e f in ite  shape" (Burlinson, 
1968). Although the name derives from the c irc u la r  f l a t  shape, the 
d is t in c t iv e  c h arac te r is tic  o f a modern ta b le t  is i ts  method of creation
by compression in a die between punches. The process had been invented
by Thomas Brockedon in 1843 but i t  was not popular i n i t i a l l y  and 
medicines continued to be prepared as p i l l s ,  powders and other 
t ra d it io n a l formulations. The B r it is h  Pharmacopoeia of 1885 described 
only one ta b le t ,  glyceryl t r i n i t r a t e .  Even by the edition of 1945 only 
35 substances were described in ta b le t  form. However the tab le t  
formulation offered the advantages of accurate un it dosage, ease of 
handling by patien t and pharmacist and gave the economies of large-scale  
production. I t  became the dominant formulation for modern drugs and 
about 60% of prescriptions are now dispensed in ta b le t  form 
(Burlinson, 1968).
As the unit dosage of digoxin is so small (0.0625 - 0.25mg) 
the digoxin powder has to be mixed with several hundred times larger  
volume of excipients p r io r  to ta b le t t in g .  These excipients are not 
specified by the pharmacopoeia but are chosen by the manufacturer 
to supply bulk, lu brica tion  and d is in tegra tion  q u a l i t ie s  to the 
ta b le t  mixture. These excipients require adequate mixing with the 
digoxin powder to ensure t a b le t - to - ta b le t  consistency in digoxin 
content. The powder is then made in to  granules to give fa s t  and 
even flow into the dies o f the ta b le t t in g  machine.
The B rit is h  Pharmacopoeia of 1968 contained a number of 
regulations re la t in g  to digoxin ta b le ts .  A monograph specified  
the pu rity  of the digoxin powder -  not less than 9>6% of dry weight.
The tab le ts  had defined l im its  fo r v a r ia t io n  in weight. Content 
was to be checked by assay o f the digoxin in a sample of 20 tab le ts  
and had to be w ith in  90 -  110% o f  stated dose. The tab le ts  also 
had to pass the d is in tegra tion  rate  te s t .  This te s t  was designed 
to ensure that the tab le ts  had not been excessively compressed and 
were capable o f fragmenting rap id ly  enough in the gastro in tes tina l  
ju ices to ensure adequate release o f the drug for absorption to take 
place. This was an in v i t ro  te s t  in which 6 tab le ts  were to be placed 
in a chamber which o s c il la ted  under water. Within 15 minutes the 
tab le ts  had to d is in tegra te  and the fragments pass through the wire  
mesh of the chamber.
The pattern o f commercial production o f digoxin tab le ts  is  
large in scale and complexity. In 1972, 245 m ill io n  digoxin tab lets  
were manufactured fo r  domestic use in the United Kingdom (Committee on 
Safety o f  Medicines: personal communication). My own enquiries revealed 
tha t w ith in  th is  country digoxin tab lets  were manufactured by ju s t  over
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twenty companies. Each company made i t s  ta b le t  in a series o f  
separate batches ra ther than as a continuous process. A small 
company might make digoxin tab le ts  only occasionally, sometimes in  
response to a spec ific  order. A company with many r e ta i l  outlets  
might, i f  i ts  own manufacturing plant was busy, contract out the 
production of a digoxin batch, although th is  batch would s t i l l  be 
marketed under the companies name.
In addition B rit is h  companies exported digoxin tab lets  to 
many countries and a small quantity  were imported. An in ternatio na l  
company might manufacture digoxin tablets  of the same brand name in 
a number o f facto ries  in d i f fe r e n t  countries. Burroughs Wellcome, 
fo r  example, both exported British-produced Lanoxin tab lets  and also 
manufactured th e ir  brand,by s l ig h t ly  d i f fe re n t  techniques, in  several 
centres abroad.
Within the United S ta tes , over three dozen companies manufactured 
digoxin ta b le ts . The Food and Drug Administration reported alarming 
results re la t in g  to the q u a lity  control of American digoxin ta b le t  
manufacture (Food and Drugs Administration, 1971 ; Banes, 1971). They 
had found tha t 33 of 36 companies produced tablets  which fa i le d  to meet 
the weight, content or d is in tegra tion  rate  c r i t e r ia  o f th e ir  current 
pharmacopoeia. Inspection o f the manufacturing f a c i l i t i e s  had shown 
equipment was often excessively worn, an u n cr it ica l approach to 
biopharmaceutics was commonplace, q u a lity  control laboratories - although 
supplied with w e ll -q u a l i f ie d  s t a f f  -  had poor f a c i l i t i e s  and checks on 
ta b le t  q u a lity  were often omitted.
BIOAVAILABILITY
The term bioavail a b i l i t y  was introduced by pharmacists when 
they became aware that the way in which a drug is formulated can
determine i t s  absorption from the gut. I t  had long been realised  
th a t  on some occasions drug absorption could be impaired -  i t  was not 
rare for a p i l l  to be found in ta c t  in the faeces! (Wagner, 1971).
However th is  was a ttr ib u ted  to poor preparation by the pharmacist.
From the 1930's onwards drug formulation was increasingly in the hands 
of large pharmaceutical companies who produced a more standardised 
product, and pharmacists began to study these formulations in a 
systematic manner. The b io a v a i la b i l i ty  (sometimes called  
biological a v a i la b i l i t y ,  physiological a v a i la b i l i t y  or systemic 
a v a i la b i l i t y )  of a drug formulation is the pattern of de livery  of 
the drug into the c irc u la t io n  and tissues of the body. I t  has two 
components -  the rate at which de livery  occurs and the to ta l extent 
to which de livery  o f the dose takes place. I t  i s ,  in other words, 
about how fa s t  and how f u l ly  the formulation delivers  i ts  dose in to  
the body. The fa c t tha t b io a v a i la b i l i ty  covers two components means 
that i t  must remain a concept and not a single parameter or measurement. 
Both components were included because each may independently help to 
determine the response to the drug. The word b io a v a i la b i l i ty  needed to 
be invented because no other term covered exactly the same meaning 
or provided the same emphasis on formulation. Although absorption 
had a s im ila r  connotation fo r  oral formulations i t  did not cover 
the p o s s ib i l i ty  that a drug might be to t a l ly  absorbed from the 
gastro in tes tina l t r a c t ,  but then be metabolised during i ts  f i r s t  
pass through the l i v e r  before reaching the general c irc u la t io n . Also, 
the term b io a v a i la b i l i ty  could be applied to other methods of 
administration such as intramuscular in je c tio n .
Much o f the e a r l ie r  work on drug formulation characteris tics  
relevant to b io a v a i la b i l i ty  was done in v it ro  by measuring the rates
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at which tab le ts  dissolved and released th e ir  drug in to  solution  
(Wagner, 1971). The f i r s t  b io a v a i la b i l i ty  study is said to be that  
of Oser, Melnich and Hochberg (1945). Although others at an e a r l ie r  
date had observed the absorption o f drugs th is  was the f i r s t  study 
with the ob jective  o f assessing how formulations o f the same 
substance affected the de livery  of the drug in to the body. They 
compared preparations of vitamins and showed that the amounts excreted 
in the urine a f te r  a dose varied between formulations and did not 
corre la te  with in v i t r o  d is in teg ra tio n  times. The early  work was 
re s tr ic te d  to the few drugs whose concentrations in blood or urine could 
be measured by assays o f s u f f ic ie n t  s e n s it iv i ty .  However i t  soon 
became necessary to devise ways of quantifying the d ifferences in  
b io a v a i la b i l i ty .  The problem was that drug concentration changes could 
normally only be measured in  the accessible body f lu id s  such as blood 
and urine. The solution was found in the compartmental theory, introduced 
by Teorell (1937) but developed by Riegelman, Loo and Rowland (1968).
This conceived the body tissues as s im p lif ied  into sets of homogenous, 
discrete  compartments. In the most simple version, the one compartment 
model, the whole body was considered as a single homogenous u n it  with  
the blood being representative of a l l  other tissues. In the 
two-compartment model the blood was considered part o f a central 
compartment into which drug absorption took place and from which a l l  
excretion occurred. A second peripheral compartment represented the 
less highly perfused tissue s ite s .  The drug diffused b id ire c t io n a l ly  
between these compartments in a manner dependant on the drug 
concentration in each and on the resistance to d iffu s ion  as represented 
by a rate constant. Models o f th ree , four etc compartments could be
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devised but in each case the movement o f drug would be defined by a 
series o f  rate  constants and the to ta l amount of drug entering the 
system. The compartment theory allowed measurements o f drug 
concentrations in the blood (centra l compartment) to be used to 
describe the movement of drug in the body as a whole. The v a l id i ty  
o f  a compartment model could be assessed by following blood concentrations 
a f te r  an intravenous dose of the drug and observing i f  the curve of 
decline in drug concentration a f te r  in je c tio n  f i t t e d  with the pattern  
predicted by compartmental analysis. The compartment concept g reatly  
stimulated the study o f 'pharmacokinetics' i . e .  the study o f the 
t im e -p ro f i le  o f drug concentration changes in the body. By the early  
1970's th is  work had begun to be summarised and published fo r  a wider 
audience (Wagner 1971, Notari 1971 and Gibaldi 1971).
In practice most drugs obeyed f i r s t -o r d e r  k inetics  ( i . e .  the 
amount o f drug d iffu s ing  out o f the compartment was d ire c t ly  proportional 
to the concentration remaining) and one, two or occasionally three  
compartment models were s u f f ic ie n t  to describe accurately a drug's 
k in e tic s . From the mathematical models several p ractical indices fo r  
assessing b io a v a i la b i l i ty  could be derived. A fte r  a single dose the 
area under the tim e-p lo t o f  drug concentration in the blood, when 
extrapolated to i n f i n i t y ,  is d i re c t ly  proportional to the amount absorbed 
in to  the c irc u la t io n . With repeated dosing, drug concentration rises  
to reach a 's tead y-s ta te ' at which input balances output. The time to 
reach steady s tate  can be predicted from the e lim ination h a l f - l i f e  
of the drug. The rate of r ise  is exponential and is 93.75% completed 
(50 + 25 + 12.5 + 6.25%) a f te r  4 h a l f - l iv e s .  At steady state the area 
under the time p r o f i le  of drug concentration between doses is a d ire c t
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index o f the extent o f absorption. The drug concentration immediately 
p rio r  to a dose at steady state is also d ire c t ly  proportional to the 
extent o f absorption, providing absorption is not s t i l l  occurring.
The to ta l amount o f drug excreted in the urine a f te r  a single  dose is  
also proportional to the amount absorbed, and at steady state  the amount 
excreted in the urine between doses p a ra lle ls  the extent of absorption. 
The derivation of these indices from the compartmental models was 
described by Wagner (1971), Notari (1971), Gibaldi (1971) and 
Greenblatt and Koch-Weser (1975).
None of these indices is  expressed in absolute units of  
absorption and b io a v a i la b i l i ty  must be expressed r e la t iv e  to another 
formulation. The re la t iv e  b io a v a i la b i l i ty  of an oral formulation is  
defined by comparison with a standard l iq u id  preparation. There is 
no "gold standard" l iq u id  formulation and as absorption can be influenced  
by the volume and type of solvent and by the position and feeding o f  
the subject the nature of the solution and the circumstances of i t s  
administration should always be stated (American Pharmaceutical 
Association, 1972). Since absorption even from a solution may be 
incomplete, the absolute b io a v a i la b i l i ty  is found by comparison with  
an intravenous dose.
These methods of assessing b io a v a i la b i l i ty  assume that the drug 
is e ith e r  not metabolised or that metabolism follows a fixed pattern  
d ire c t ly  proportional to the concentration of unchanged drug. Metabolism 
o f drugs is d i f f i c u l t  to study in f u l l  and for many medicines th is  type 
of knowledge is very incomplete. The pharmacokinetics o f metabolites 
are seldom known. In th is  respect the d ig i t a l is  glycosides have been 
investigated to an unusual ex ten t, p a r t ic u la r ly  fo r  d ig itox in
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(S to rs te in , 1981) and digoxin (Reitbrock and Woodcock, 1981). The 
fa c t  that metabolism can a f fe c t  measures of b io a v a i la b i l i ty  o f  
digoxin has been shown by the differences found in urinary excretion  
when digoxin is given intravenously at d i f fe re n t  infusion rates ,  
Greenblatt et a l . ,  (1974) found tha t a bolus dose o f digoxin produced 
9% less 6 day cumulative urinary excretion of d igoxin, measured by 
radioimmunoassay, than a f te r  infusion of the same dose over 1 hour. 
Marcus et a l . ,  (1976) found that a 3 hour infusion led to 21% higher 
excretion than a 1 hour infusion ra te . These differences have been 
in terpreted as due to higher plasma digoxin concentrations pertaining  
a f te r  rap id ly  administered doses inducing greater hepatic metabolism 
(S to l l  and Wagner, 1975). A s im ila r  phenomenon, but present to a 
small extent, is l i k e ly  to occur when oral formulations produce 
d if fe r e n t  peak levels of drug in the blood. The radioimmunoassay fo r  
digoxin detects the card io -ac tive  metabolites but not the 
c ard io -in active  ones and th is  " far-s ighted" (Larbig and Kochsiek, 1972) 
c h arac te r is t ic  makes the assay generally  su itab le  fo r b io a v a i la b i l i ty  
studies. This however is  true only with h igh-quality  antibodies and 
Rietbrock, Vohringer and Kuhlmann (1977) found one commercial digoxin 
radioimmunoassay which p a r t ia l ly  cross-reacted with the card io -inactive  
metabolite dihydrodigoxin.
There is therefore a choice of methods availab le  when designing 
a b io a v a i la b i l i ty  study. The methods chosen w i l l  depend in part on the 
objectives o f the study, the f a c i l i t i e s  ava ilab le  and the nature of 
the drug. Single dose studies require subjects for whom the drug 
is not essentia l. Normal subjects are often sought as they are 
assumed to have normal drug elim ination c a p a b il i t ie s  and to show less
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in te r -  and in t r a -  subject v a r ia b i l i t y  than patients (American Pharmaceutical 
Association, 1972). Single dose studies have the disadvantage th a t a 
very large number of samples has to be assayed to portray accurately the 
blood drug concentration p r o f i le .  I f  a drug has a long elim ination  
h a l f - l i f e ,  as does digoxin, the co llection  of blood and urine should 
be over a period o f days and i t  can be d i f f i c u l t  to f ind subjects 
able to be availab le  fo r  these periods of time. Studies with  
measurement o f  steady state  blood or urine drug concentrations have 
the advantage that they more closely resemble the chronic use of the 
drug in c l in ic a l  practice but do involve more exposure to the drug 
effects  (Levy 1974). Steady state  measurements have been stated to 
be the most c l in ic a l ly  re levant index of b io a v a i la b i l i ty  (Greenblatt,
Smith and Koch-Weser 1976, K eller  and Rietbrock 1977). I f  the subjects 
are patients i t  may be possible to record differences in therapeutic  
a f fe c t ,  but care must be taken to avoid any important d e te r io ra tio n  
in th e ir  health (Koch-Weser, 1974). The immediate pre-dose drug 
concentration in the blood at steady state  has the advantage o f  
s im p lic ity  but is sensitive  to the precision of the assay used.
Accurate measurement o f drug excreted in the urine requires very 
conscientious co llection  of urine output.
By the s ta r t  of the 1970‘ s the concept of b io a v a i la b i l i ty  and 
i ts  methods of measurement were well known to academic pharmacists, 
although s t i l l  un fam ilia r to most c l in ic ia n s . In 1961 s u f f ic ie n t  
evidence (mostly from in v i t ro  experiments) had accumulated to allow  
Levy and Nelson (1961) to predict th a t the d is in tegra tion  rate  tes t  
o f the pharmacopoeia would be inadequate to prevent s ig n if ic a n t  
differences in b io a v a i la b i l i ty  of generic formulations o f some drugs.
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Ten years la te r  Wagner (1971) summarised a l l  the studies to date 
which had shown va ria t io n  in bioavail a b i l i t y  fo r  drug products of 
nominal s im i la r i ty .  The m ajority  o f these reports involved 
a n t ib io t ic s ,  analgesics or vitamins, fo r  which a modest v a r ia t io n  in 
b io a v a i la b i l i ty  was not o f  therapeutic importance. However more 
crucial examples had emerged in c l in ic a l  practice. The anticoagulant 
e ffe c t  o f warfarin  was found to have been modified by a lte ra tions  
in the formulation o f  a Canadian brand of the drug (Losinski, 1960).
A fa i lu r e  to control diabetes due to formulation e f fe c t  was found 
with some brands of tolbutamide (Carter 1963, Carminetsky 1963). In  
A ustra lia  an outbreak o f phenytoin to x ic i ty  occurred when a 
pharmaceutical company changed one of the excipient substances, 
resu lting  in greater absorption o f  phenytoin (Tyrer et a l . ,  1970).
Azarnoff and Huffman (1976) have more recently summarised the reports 
showing differences in b io a v a i la b i l i ty  o f therapeutic importance.
The lim ited  dissemination of the b io a v a i la b i l i ty  concept by 
1970 was re flec te d  by the fa c t  th a t no pharmaceutical company was, 
to my knowledge, a c t iv e ly  concerned at that time about the b io a v a i la b i l i ty  
of i ts  digoxin tab le ts  althoughdigoxin had precisely the characteris tics  -  
low water and l ip id  s o lu b i l i t y ,  incomplete absorption from a so lu tion ,  
and narrow tox ic -therapeutic  ra t io  -  which Levy and Nelson in 1961 had 
predicted would lead to b io a v a i la b i l i ty  problems.
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CHAPTER 2
PRELIMINARY STUDIES ON THE BIOAVAILABILITY OF DIGOXIN TABLETS
INTRODUCTION
My in te re s t  in the b io a v a i la b i l i ty  of digoxin developed as 
the resu lt  of facing a c l in ic a l  problem in one p a t ie n t ,  M.P. This 
patien t had recurrent attacks o f  a t r i a l  f i b r i l l a t i o n .  When I f i r s t  
encountered M.P. a t the ou t-p a tien t c l in ic  of S t. Bartholomew's 
Hospital in 1971 these attacks had not been controlled by high doses 
of oral digoxin. The discovery that she had a low concentration of 
digoxin in her blood led me to investigate  her absorption of digoxin.
This case made me examine the l i t e r a tu r e  on digoxin and I found 
th a t l i t t l e  had been published about the use of plasma digoxin 
concentrations to help achieve sa t is fac to ry  d ig i ta l is a t io n ,  although the 
radioimmunoassay of digoxin had become availab le  two years e a r l ie r .
I decided to measure plasma digoxin concentrations in 100 consecutive 
patients who were attending the cardiac follow-up c l in ic  and who were 
receiving digoxin treatment. This study had two objectives: (1) to assess 
the frequency o f digoxin to x ic i ty  in out-patients and (2) to establish  
i f  there were other patients s im ila r  to M.P. who had low plasma digoxin 
concentrations despite an apparently adequate dose. I intended to 
follow-up the subgroup of patients with low digoxin concentrations 
and to determine th e i r  optimal digoxin dosage requirements, i . e .  the 
d a ily  dose which would give adequate control of th e ir  a t r ia l  f i b r i l l a t i o n  
o r, i f  they were in sinus rhythm, the dose which produced plasma digoxin 
concentrations of 1.0 ^ 2.0ng/ml. This was the range of digoxin 
concentrations in the blood which Chamberlain et a l . ,  (1970) had 
suggested as the 'therapeutic  range'. By the time the survey began
reports had come from the United States (Lindenbaum et a l . ,  1971) 
and Finland (Manninen et a l . ,  1971) that d i f fe re n t  brands of digoxin 
ta b le t  produced differences in plasma digoxin concentration. I t  
was decided to record the brand of ta b le t  used by each of the patients  
The orig ina l objectives of the survey of out-patients  were 
superceded when i t  became evident that in an occasional patient  
a change in digoxin formulation could produce an important 
a lte ra t io n  in th e ir  s tate  of d ig i ta l is a t io n .  The results of the 
ou t-p atien t survey and the follow-up studies in individual patients  
were therefore examined from the point of view of the b io a v a i la b i l i ty  
of the ta b le t  brands.
Since an i n i t i a l  ob jective  was to study how d ig i ta l is a t io n  of 
patients could be improved the doses of digoxin were often changed 
in a way which was not id e a l ly  suited to a b io a v a i la b i l i ty  study.
I have however devoted this chapter to these early  studies and 
shall describe them in some d e ta il  as they formed the essential 
sta rting  point fo r  the future  experiments by indicating that there  
was a b io a v a i la b i l i ty  problem with digoxin ta b le ts .
METHODS
Radioimmunoassay o f digoxin
The measurements of the plasma concentration of digoxin in th is  
chapter, and in a l l  subsequent parts of my digoxin b io a v a i la b i l i ty  
studies, was by radioimmunoassay.
The radioimmunoassay technique had been conceived by Yalow 
and Berson (1960) fo r  measurement of poly-peptide hormones. O liver  
et a l . ,  (1968) applied th is  technique to the measurement of d ig ito x in  
in serum. Butler et a l . ,  (1967) succeeded in ra is ing s p e c if ic ,  high
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a f f in i t y  antibodies to digoxin in rabbits using digoxin-albumin 
conjugates. Smith et a l . ,  (1969) in  Boston used th is  antibody to 
develop a radioimmunoassay which was s u f f ic ie n t ly  sensitive  to 
measure the concentration o f digoxin in the plasma of patients .
During a c l in ic a l  attachment from S t. Bartholomew's Hospita l,
Dr Douglas Chamberlain worked in Smith's department at the 
Massachussets General Hospital and on his return he brought with him 
supplies of the digoxin antibody which were then used to estab lish  
a s im ila r  assay procedure in London. In 1970 the antibody produced 
in Boston was replaced with a digoxin antibody o f s im ila r  characteris tics  
raised in rabbits in London.
The St. Bartholomew's Hospital assay procedure has been described 
by Chamberlain e t a l . ,  (1970). Samples of heparinised blood were 
centrifuged to obtain plasma which was stored at -10°C u n ti l  assayed.
Each blood sample was assayed in duplicate by taking two 1ml aliquots  
of plasma. To an a liquot was added 2.2ng of t r i t i a t e d  digoxin 
(sp e c if ic  a c t iv i ty  3.2C1 per mM : MEN chemicals, Dreieichenhain bei 
Frankfurt/Main, Germany). Digoxin antibody was then added in a quantity  
which had been previously found s u f f ic ie n t  to bind 55% o f the t r i t i a t e d  
digoxin in the absence of any unlabelled drug. The mixture was 
incubated at room temperature fo r  a t  least 15 minutes. The 
anti gen-anti body complex was separated from the unbound digoxin by 
absorption of unbound digoxin onto dextran-coated charcoal which was 
then precip ita ted  by cen tr ifugatio n . The supernatant was added to 
10ml liq u id  s c in t i l la t io n  medium (Bray's solution or NE 250 [Nuclear 
Enterprises Ltd, S ig h th i l l ,  Edinburgh]) and heated at 80°C in an oven 
for  60 minutes to complete dénaturation of the antibody and hence 
release to digoxin from the binding s ite s . Centrifugation was used to
pack the precip ita ted  protein as f irm ly  as possible to the bottom 
of the counting ph ia ls . The supernatant underwent counting in a 
Beckman LS100 liq u id  s c in t i l la t io n  counter. Quenching due to plasma 
constituents was corrected fo r  by use of in ternal standards. Percentage 
binding of t r i t i a t e d  digoxin was then calculated. The concentration of 
digoxin in the sample was obtained from standard curves produced at  
each assay run by assaying a series of solutions prepared by adding 
known amounts o f c ry s ta l l in e  digoxin (B r it is h  Pharmacopoeia Commission) 
to pooled normal human plasma.
In th is  form the assay method had a s e n s it iv i ty  which enabled 
plasma digoxin concentrations down to 0.25ng/ml, the lower end of the 
standard curve, to be measured.
Several non-glycoside stero id  substances -  cho lestero l, c o r t is o l ,
17B o es trad io l,  dehydroepiandrosterone, progesterone and testosterone - 
were assessed and found not to cause interference with the assay.
Two q u a lity  control studies of the accuracy and precision of the 
assay were performed during the period coinciding with the b io a v a i la b i l i ty  
studies. In 1971 measured quantit ies  of c ry s ta l l in e  digoxin were 
added to pooled normal human plasma to provide plasma digoxin concentrations 
of 1, 2 and 3ng/ml. These samples were coded so that they were not 
id e n t i f ia b le  during the assay procedures. The results were:-
Ing/ml sample -  mean 0.90ng/ml (30 estimations)
S.D. 0.15
2ng/ml sample - mean 1.90ng/ml (11 estimations)
S.D, 0.15
3ng/ml sample - mean 2.84ng/ml (30 estimations)
S.D. 0.19
During 1972 a s im ila r  q u a lity  control study was carried out 
with samples containing 1 -  4ng/ml of digoxin. The results were:-
1.0ng/ml sample - mean 0.85ng/ml (11 estimations)
S.D. 0.05
1.5ng/ml sample - mean 1.46ng/ml (12 estimations)
S.D. 0.05
2.0ng/ml sample - mean 1.92ng/ml (18 estimations)
S.D. 0.10
2.5ng/ml sample -  mean 2.43ng/ml (12 estimations)
S.D. 0.15
3.0ng/ml sample - mean 2.92ng/ml (18 estimations)
S.D. 0.15
4.0ng/ml sample -  mean 4.02ng/ml (IB estimations)
S.D. 0.22
All of the plasma digoxin assays (including the q u a lity  control 
assays) were performed by M.R. Howard with the exception of the assay 
results given in Chapter 5 which were performed by Helena Greenwood.
STUDIES IN INDIVIDUAL PATIENTS
Patient M.P.
M.P. was a 50 year old woman who had attacks of paroxysmal 
a t r ia l  f i b r i l l a t i o n .  She had f i r s t  attended St. Bartholomew's Hospital 
in January 1971 when she was admitted v ia  the Emergency Medical 
Department a f te r  presenting with p a lp ita t io n  and breathlessness. She 
was found to have id iopath ic  a t r ia l  f i b r i l l a t i o n  and mild 
pulmonary oedema. She reverted to sinus rhythm a f te r  intravenous 
d ig i ta l is a t io n .  She was prescribed digoxin 0.25mg/day on discharge.
The next month she was readmitted with a fu rther paroxysm of a t r ia l  
f i b r i l l a t i o n .  Practolol lOOmg B.D. was added to her regime. She 
was referred to the Cardiology C lin ic  fo r  follow-up. In July 1971 she 
reported having had several more short bursts of p a lp ita t io n . Her 
digoxin was increased to 0.75mg/day.
I met M.P. when she attended the c l in ic  in September 1971. She 
had continued to experience p a lp ita t io n . Her practolol dose was 
increased to 200mg B.D. On her return to the c l in ic  two weeks la te r  
she reported 5 fu r th e r  attacks, A blood sample was taken for measurement 
of plasma digoxin concentration to assess her degree of d ig i ta l is a t io n .  
The digoxin concentration was at the lower end of the normal therapeutic  
range at 1.0ng/ml but I then realised that the blood sample had been 
taken only a few hours a f te r  her la s t  dose. She returned fo r  a fu r th e r  
estimation and a sample was collected 12 hours a f te r  the preceding 
digoxin dose ; plasma digoxin concentration was reported as being less 
than 0.5ng/ml. The importance of taking her tab le ts  regu larly  was 
emphasised to her - she did claim to have done so previously -  and 
a fu rth e r  sample was taken 2 weeks la te r .  I t  again contained less than
0.5ng/ml digoxin in the plasma. A fu rth e r  specimen produced the same 
re s u lt .
She was then admitted to the ward on 18/10/71 to investigate  the 
cause of her low digoxin lev e ls . A fte r  a period of 6 days without 
digoxin and following an overnight fa s t  she was given 0.5mg digoxin 
with 50ml water, using the Boots Ltd brand of digoxin tab lets  which 
she had used as an o u t-p a t ie n t .  Blood samples fo r  measurement of 
plasma digoxin concentration were taken before the dose and fo r  8 hours 
a f te r .  The results are shown in Figure 1. The plasma digoxin
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Figure 1 Plasma digoxin concentrations recorded in patient
M.P. a f te r  0.5mg doses of Boots Ltd. digoxin tab le ts  
on the f i r s t  occasion ( 0 - 8  hours, closed c irc le s )  
and second occasion ( 0 - 1 6  hours, open c ir c le s ) .  
Results obtained in normal subjects by White et a l . ,  
(1971) are also shown (crosses).
concentrations were considerably lower than those found by Doherty (1961),  
Marcus et a l . ,  (1966) and White e t a l . ,  (1971) a f te r  the same dose 
given to fasting  subjects. The absorption curve recorded by White 
and colleagues in normal subjects at St. Bartholomew's. Hospital is 
included in Figure 1. They had used Lanoxin ta b le ts . In th e ir  study 
the peak digoxin concentrations had occurred at 1 hour, whereas in 
M.P.'s absorption curve the peak concentration was a t 7 hours. Since 
th is  peak level occurred near the end of the sampling period the absorption 
te s t  was repeated four days la te r  with blood samples taken up to 16 hours 
a f te r  the dose: these results are also shown in Figure 1. No additional 
peak was seen in th is  extended absorption curve. An intravenous bolus 
dose of 0.5mg digoxin was given and frequent blood samples were taken 
over the i n i t i a l  3.5 hours. The plasma digoxin concentrations recorded 
a f te r  th is  intravenous dose were considerably higher than those found 
a f te r  the oral doses: between 15 minutes and 3 hours a f te r  the 
intravenous dose the plasma digoxin concentration f e l l  from 8.0 to 
1.9ng/ml. The mean of two samples taken 30 hours a f te r  the intravenous 
dose was 0.9ng/ml, This indicated tha t her h a l f - l i f e  of e lim ination  
of digoxin was approximately the same as the normal value o f 36 hours 
found in patients with good renal function (Doherty, 1968).
In view of M .P.'s  abnormal digoxin absorption curve i t  was decided 
to look fo r  other evidence o f in te s t in a l malabsorption. The results  
re la t in g  to th is  were as fo llo w s:-
Haemoglobin level : 14.7G/I00ml
Peripheral blood film  
Serum • 385pg/ml
Serum fo la te  : 2.5ng/ml
normal
normal
normal
normal
Red c e ll  fo la te  
Serum i ron
Iron binding capacity  
Total plasma protein  
Albumin
Plasma calcium
Plasma phosphate
A lkaline  phosphatase
3-day faecal f a t  
excretion
Glucose tolerance  
te s t
Xylose tolerance te s t  
(50G dose)
Lactose tolerance  
te s t
257ng/ml 
lOOpg/IOOml 
335ug/100ml 
7 .5G/100ml 
4.0G/100ml 
9 . 7mg/100ml 
2.5mg/100ml 
57 I .U .
3.7G
fasting  78mg/100ml 
peak 178mg/100ml 
at 90 mins
44mg/100ml at 
90 mins
r is e  o f blood 
glucose of 
46mg/100ml
normal
normal
normal
normal
normal
normal
normal
normal
normal
normal
normal
normal
Barium meal and 
follow through
Histology from biopsy 
o f small in tes t in e  
(obtained with a
Crosby capsule) : normal
There was therefore no evidence of malabsorption. To te s t  i f  
she had a very spec if ic  absorption defect she was given a 100mg oral 
dose of hydrocortisone which, l ik e  digoxin, has a basic steroid  
molecular structure . Her plasma cortiso l level rose from 11.5pg/100ml 
before the hydrocortisone dose to reach a peak level o f 95pg/100ml at 
1 hour a f te r  the dose. This rapid r is e  to a high peak level suggested 
that her absorption o f steroids was not abnormal.
I t  was concluded at th is  stage th a t her impairment of absorption 
was lim ited to digoxin. I t  was decided to increase progressively her
digoxin dosage u n ti l  a plasma digoxin concentration of between 1 and 
2ng/ml was achieved. She was continued on the Boots brand of digoxin 
and over the subsequent weeks her dosage was increased at 1 -  2 week 
in te rv a ls .  The plasma digoxin concentrations found at each dosage 
level are shown in Figure 2. The blood sample fo r  plasma digoxin 
concentration was now always taken a t 9 -  10 hours a f te r  the preceding 
digoxin dose in view of her prolonged absorption time. Only at 
remarkably high doses o f 1.75mg/day or more did she reach a plasma 
digoxin concentration above Ing/ml. During th is  period she continued 
to have attacks of a t r ia l  f i b r i l l a t i o n  s u f f ic ie n t ly  frequently  that  
paroxysms o f the arrhythmia were recorded on three v is i ts  to the c l in ic .  
The v e n tr icu la r  rates which were recorded during these episodes are 
included in Figure 2. The v e n tr ic u la r  ra te  during the paroxysm tended 
to be slower as digoxin level increased, although i t  was rapid even
when the plasma digoxin concentration exceeded 1.0ng/ml.
In January 1972 the pa tien t was admitted to S t. Bartholomew's 
Hospital because of chest pain and breathlessness associated with a 
prolonged attack o f a t r i a l  f i b r i l l a t i o n .  I t  was decided to stop her 
digoxin treatment and to begin therapy with qui nidi ne (given as Kinidin  
durules, one 4 times per day) and propranolol (40mg QID). On th is  
regime her attacks of a t r ia l  f i b r i l l a t i o n  were s t i l l  present but less 
frequent. By 2nd March 1972 i t  was f e l t  that digoxin should be added 
to her regime and that Lanoxin should now be used to te s t  i f  i t  gave 
improved plasma digoxin le v e ls . The plasma digoxin concentrations 
found a f te r  her f i r s t  0,5mg dose of Lanoxin are in Figure 3. The Lanoxin 
tab lets  gave a s l ig h t ly  greater peak level than had been found a f te r  the
same dose of Boots digoxin but absorption was much more rapid , with the
2002 . 0 r
"  " O 1 5 0  f .E
1
5o c
B
i
C L .
1 .7 55 1 .0  1 .2 5  1
DIGOXIN DOSAGE ( m g / d a y ]
0 .2 5
Figure 2 Plasma digoxin concentrations recorded in patient M.P, 
during maintenance therapy with Boots digoxin tab le ts  
(closed c irc le s )  and the ven tr icu la r  ra te  recorded 
during attacks o f  a t r ia l  f i b r i l l a t i o n  (open c irc le s ) .
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Figure 3 Plasma digoxin concentrations recorded in patient
M.P. a f te r  0.5mg doses of Boots digoxin tablets  (A), 
Lanoxin tab le ts  (B) and capsules containing the 
Boots tab le ts  ground to a fine powder (C).
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peak level occurring at 30 minutes a f te r  the dose. During maintenance 
therapy of 0.5mg/day of Lanoxin, blood samples were taken fo r  plasma 
digoxin estimation a t 1, 2, 6 and 8 weeks: each sample was again 
taken 9 - 1 0  hours a f te r  the digoxin dose. Considerably higher plasma 
digoxin concentrations of 1 .7 , 1 .3 , 1.4 and 2 . Ing/ml were recorded on 
these occasions. An episode o f a t r ia l  f i b r i l l a t i o n  had a ven tr icu la r  
rate  of 144 beats/min when the digoxin concentration was 1.3ng/ml.
The Boots and Lanoxin tab le ts  used by M.P, were submitted 
fo r  pharmaceutical analysis. These were carried out fo r  me by 
Mr. Henry Davis o f Harris Pharmaceuticals L td . ,  London, Both the Boots 
brand and Lanoxin (batch 2675) were w ith in  the B rit ish  Pharmacopoeia 
(1968) standards of weight and size fo r  digoxin ta b le ts . The B.P. 
dis in tegra tion  rate  te s t  (modified by Mr. Davis to include a smaller 
size o f mesh, gauge 25) gave results w ith in  the permitted l im i t  of 
15 minutes: Lanoxin -  4 minutes, and Boots brand -  2 minutes. To
te s t i f  the Boots tab le ts  had been excessively compressed during the 
ta b le t t in g  process the pressure required to cause ta b le t  f rac tu re  was 
measured. Five tab le ts  of each brand were tested. The mean pressure 
to cause collapse or capping of the Lanoxin tab lets  was 6.2Kg 
(range 5.8 -  6 .4 )  while the mean pressure to disrupt the Boots digoxin 
ta b le t  was 1.7Kgm (range 1.1 - 3 .1 ) ,  i . e .  27% of that required to 
disrupt the Lanoxin ta b le ts . Assay of the digoxin content o f single  
tab lets  was also carried out using a method based on the B rit is h  
Pharmacopoeia (1968) assay for digoxin content. The content of 10 Lanoxin 
0.25mg tablets  ranged from 75 to 110% of stated dose and averaged 88%.
The Boots tab lets  gave an average content of 85% of stated dose and 
ranged from 66 to 117%. The accuracy and reproducabi1i t y  of th is  single
b1
ta b le t  digoxin assay had not been established by Mr. Davis but i t  was 
f e l t  reasonable to conclude that the Boots tab lets  contained an 
approximately s im ila r  amount of digoxin to that of the Lanoxin.
On 3rd May 1972 these results were discussed with Mr. A.C. Caws 
of the Quality  Control Department of Burroughs Wellcome a t D artford ,  
Kent. Mr. Caws told me that Burroughs Wellcome performed a check 
of digoxin content on a combined sample of 20 tab le ts  from each 
production batch of Lanoxin, as required by the B r it is h  Pharmacopoeia, 
and he f e l t  that Henry Davis's estimate of 88% of stated content fo r  
Lanoxin was too low and probably re flected  underestimation by his 
assay method. Burroughs Wellcome also carried out assays of single  
ta b le t  content, although th is  was not required by the Pharmacopoeia, 
and Mr. Caws undertook to review the results of recent batches. I 
enquired i f  i t  was possible to measure p a r t ic le  size of digoxin w ith in  a 
ta b le t .  Mr. Caws explained th a t the presence of excip ient materials in 
a digoxin ta b le t ,  which constitu te  99,8% of the ta b le t  weight, made i t  
extremely d i f f i c u l t  to examine p a r t ic le  size of digoxin alone but 
microscopy of a fragmented ta b le t  gave a rough estimate of digoxin 
p a r t ic le  s ize . He subsequently carried microscopic analysis of the 
digoxin tab le ts  used by M.P. with the following resu lts: Lanoxin -  
digoxin p a r t ic le  diameters ranged from 3 -  50pm; Boots tab lets  - 
p a r t ic le  diameters from 10 -  50pm. I t  was not possible to d i f fe r e n t ia te  
the digoxin partic les  s u f f ic ie n t ly  to measure a mean value.
Despite the fa c t that th is  pharmaceutical analysis had not 
revealed any major differences between the Boots and Lanoxin ta b le ts ,  
the fa s te r  absorption and higher plasma digoxin concentrations found 
with Lanoxin indicated that there was some c h arac te r is t ic  of these
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tab le ts  which affected digoxin absorption. I decided therefore  
to assess the e f fe c t  o f grinding the Boots tab le ts  into a f in e  
powder and administering th is  powder w ith in  a so ft  ge la tin  capsule.
The Boots tab lets  were ground by myself into a very f in e  powder using 
a standard ward mortar and pestle . The powder from two 0.25mg tablets  
were inserted into each capsule. One such capsule was taken by M.P. 
each morning as replacement o f her Lanoxin ta b le ts . The r ise  in  
digoxin level recorded during 2 hours of her f i r s t  0.5mg digoxin 
capsule dose are shown in Figure 3: th is  dose followed previous 
treatment with Lanoxin 0.5mg/day and the plasma digoxin concentration 
prio r  to ingesting the capsule was 2 . Ing/ml. Blood samples were also 
taken a f te r  7 and 10 days of encapsulated digoxin therapy, with the 
samples taken 9 hours a f te r  the dose. Her plasma digoxin concentrations 
while taking the capsules were 3,5 and 2.3ng/ml. She did not have 
any symptoms or signs o f digoxin to x ic i ty  despite these high leve ls .
She returned to treatment with Lanoxin 0.25mg BD in combination 
with the Kinidin durules and propranolol.
Patient L.S.
I f i r s t  met this 61 year old man at the cardiac ou t-p a tien t c l in ic  
on 11/2 /72. He had m itra l valve disease and chronic a t r ia l  f ib r i l l a t io n ,  
He was taking 0.75mg/day of digoxin and used tablets  manufactured by 
Harker-Stagg Ltd. His resting ve n tr ic u la r  rate was uncontrolled at 
138 beats/min: the plasma digoxin concentration was low at 0.5ng/ml.
Two fu rth er  recordings of plasma digoxin concentration were made at 
weekly in terva ls  at the same d a ily  dose of this brand and plasma 
digoxin concentrations of 0.5 and G.7ng/ml were found. The r is e  in 
digoxin concentrations recorded during 6 hours a f te r  a 0.5mg dose o f
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Harker-Stagg digoxin given with 50ml water when fasting  are shown 
in Figure 4. The digoxin level p r io r  to th is  dose was 0.7ng/ml. The 
low digoxin concentrations during regular digoxin therapy and the 
small peak r is e  a f te r  the O.Smg dose suggested that digoxin absorption 
was incomplete. In view of the results found in M.P. i t  was decided 
to change L .S .'s  digoxin brand to Lanoxin. A fte r  2 weeks on O.Smg/day 
of Lanoxin he had a plasma digoxin concentration of 1 . Ing/ml. His 
Lanoxin dosage was increased to 0.75mg/day and on blood sampling at  
subsequent weekly in terva ls  the digoxin levels were 1 .0 ,  0.7 and 
0.7ng/ml. His mean v e n tr ic u la r  ra te ,  at re s t ,  during treatment with  
Harker-Stagg tablets  was 135/min (S.D. 3) while on Lanoxin the mean 
rate was 97/min (S.D. 7 ) .  This d ifference in heart ra te  was, by 
the unpaired t  t e s t ,  s t a t i s t ic a l ly  s ig n if ic a n t  (p < 0 .0 1 ) .  The peak 
r ise  in plasma digoxin a f te r  a O.Smg dose of Lanoxin when fasting was 
0.9ng/ml (Figure 4) compared with the 0.5ng/ml r ise  with Harker-Stagg 
ta b le ts . The Harker-Stagg tab le ts  were analysed in a manner s im ila r  
to those of patien t M.P. The mean ta b le t  content of digoxin was 
estimated to 83.3% of the stated dose with individual tab lets  varying 
from 74% to 104%. The d is in tegra tion  time was 10 minutes. Pressure 
to cause ta b le t  frac tu re  was 47% of that required for Lanoxin.
Digoxin p a r t ic le  size was found at microscopy to vary from 6 to 150p. 
This patient was la te r  given a O.Smg encapsulated dose of his 
orig ina l tab lets  a f te r  grinding in the mortar and pestle . The peak 
r is e  in blood digoxin concentration is included in Figure 4. A fter  
1 and 2 weeks of a d a ily  0.5mg capsule dose the digoxin concentration 
in the plasma was 1.7 and 1.3ng/ml respectively .
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Figure 4 Increase in plasma digoxin concentration recorded in 
patient L.S. a f te r  O.Smg doses o f Marker Stagg 
digoxin tab lets  (A ), Lanoxin tablets  (B), and 
capsules containing the Marker Stagg tab le ts  ground 
to a f in e  powder (C).
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OTHER INDIVIDUAL PATIENT STUDIES 
Five other out-patients  had 2 or more estimations of plasma 
digoxin concentrations when taking Lanoxin and another brand. They 
were patients found in the o u t-p a tie n t survey to have unexpectedly 
low plasma digoxin concentrations or poor control of th e ir  a t r ia l  
f i b r i l l a t i o n .  Each lived or worked s u f f ic ie n t ly  near the hospital 
to be able to attend for several v is i t s .  As at th is  stage I had been 
in terested in determining the d a ily  digoxin dose required to achieve 
adequate d ig i ta l is a t io n  in these 're s is ta n t '  cases, more than one 
dosage level was used by each in d iv id u a l. In order to compare in  
retrospect the b io a v a i la b i l i ty  of th e ir  ta b le ts ,  the plasma digoxin 
concentrations were adjusted by d ire c t  proportion to give concentrations 
corresponding to a 0.5mg d a ily  dose. The ra tiona le  fo r  th is  
adjustment of the measured plasma concentration is that by pharmacokinetic 
theory the steady state  level during regular dosing o f a drug with  
f i r s t -o r d e r  elim ination k inetics  w i l l  increase in d ire c t  proportion to 
the d a ily  dose (Notari 1971, G iba ld i, 1971). This includes the 
assumptions that absorption from the gastro in testina l t ra c t  and any 
degradation during passage through the l i v e r  is unaffected by the 
dosage le v e l .  Since digoxin was known to have a f i r s t -o r d e r  e lim ination  
pattern and was not thought to be s ig n if ic a n t ly  metabolised during 
f irs t -p a s s  through the l iv e r  (Doherty, 1968} i t  seemed reasonable to 
apply th is  adjustment to plasma digoxin concentrations recorded during 
use of d i f fe r e n t  d a ily  dosages. Also, i t  had been shown that steady 
state  digoxin levels did increase in d ire c t  proportion to dose in 
patients who were given stepped increases of digoxin ta b le t  dosage 
(Redfors, 1972). Although I recognised that th is adjustment did not
bb
provide for ideal bioavail a b i l i t y  comparisons I f e l t  i t  was a 
useful device to allow prelim inary comparison of digoxin brands in  
a s itu a tio n  when i t  would not have been in the patients best in teres ts  
to have remained a t  a f ixed  dosage o f  digoxin fo r  prolonged periods 
of time. Although one could re ad ily  see that the plasma digoxin 
concentrations recorded in pa tien t M.P. as her Boots ta b le t  dosage 
increased from 0.25 to 2.0mg/day had a d i f fe re n t  re la tionsh ip  to 
dosage compared with those found when she took 0,5mg o f Lanoxin 
per day, th is  adjustment process permitted s ta t is t ic a l  comparison 
to be made between the digoxin concentrations obtained with these 
brands.
The ch aracteris tics  o f  these patients are given in Table 1.
Their  plasma digoxin concentration results are given in Table 2.
The d ifference  in the plasma digoxin concentrations of pa tien t  
M.P. were s t a t i s t ic a l ly  s ig n if ic a n t  (p < 0 .01 , unpaired t  te s t)  while  
differences in the other 6 patients did not reach s ta t is t ic a l  
significance (the p value fo r  L.S. was 0 .1 ) .
Each of these patients had plasma digoxin concentrations measured 
for 6 hours a f te r  0.5mg doses of Lanoxin and o f the other brand which 
they had been using when attending the c l in ic .  This dose was given 
with 50ml water a f te r  the pa tien t fasted overnight. The maximal 
increase in digoxin level during these absorption curves is given in 
Table 2. There was a weak c o rre la t io n  ( r  = 0 .46 , p > 0 .05 , < 0 .1 )  
between the r is e  in digoxin concentration and the pre-dose concentration  
during maintenance therapy with the same brand (Figure 5 ).
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PLASMA DIGOXIN CONCENTRATION DURING MAINTENANCE THERAPY ( n g / m l )  
[ADJUSTED TO CORRESPOND TO 0.5 m g /d a y  DOSE]
Figure 5 Relationship between peak r is e  in plasma digoxin 
concentration a f te r  O.Smg oral digoxin dose and 
pre-dose plasma digoxin concentration during 
maintenance therapy with the same brand of 
ta b le ts . Closed c irc les  = Lanoxin, open c irc les  
= other brands. Digoxin concentrations for  
maintenance therapy have been adjusted to 
correspond to a O.Smg/day dose (see t e x t ) .
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SURVEY OF OUT-PATIENTS
The casenotes of a l l  patients attending Dr. John Hamer's 
afternoon follow-up o u t-p a tien t c l in ic  during the period 12th February 
- 12th June 1972 (excluding a 2 week vacation in te rv a l)  were 
reviewed. Those patients on digoxin treatment were interviewed.
The age, sex, c l in ic a l  diagnosis and drug treatment were recorded 
and th e ir  weight and height were measured. Each pa tien t was questioned 
about th e ir  digoxin dosage and the time in terva l since th e ir  la s t  dose. 
A 20ml sample o f venous blood was taken fo r  estimation of urea and 
e le c tro ly te s ,  thyroid function tests and plasma digoxin concentration: 
the sample was timed to be 6 -  10 hours a f te r  th e ir  la s t  digoxin dose.
A 12 lead electrocardiogram and 60 second rhythm s tr ip  were recorded.
Patients who had not brought th e ir  tab lets  to the c l in ic  were 
asked to send an example of th e ir  current digoxin tabletand the name 
and address of the pharmacist who had dispensed th e ir  prescrip tion .  
Lanoxin tab lets  could be id e n t i f ie d  by th e ir  c h a rac te r is t ic  markings. 
When the ta b le t  was seen to be other than Lanoxin the pharmacist was 
contacted by telephone and asked for the name of the manufacturer whose 
digoxin brand he used. In some instances the r e ta i l  pharmacist had 
obtained his supplies from a wholesale chemist and was unaware of the 
manufacturer. In th is  circumstance the wholesale chemist was contacted. 
The brand of unmarked digoxin ta b le t  was able to be id e n t if ie d  in a l l  
but 11 instances: in these the r e ta i l  chemist had recently used more 
than one brand (7 cases), the patien t was unable to give d e ta ils  of the 
dispensing pharmacist (2  cases), or the patient was using a b o tt le  of 
digoxin tablets  containing a mixture from more than one prescription  
(2  cases).
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The results o f the survey were analysed a f te r  76 patients had 
been interviewed. Forty-three had been using Lanoxin and 33 used 
other brands. Seven brands other than Lanoxin were id e n t i f ie d .
As no single brand was used by more than a small number of p a tien ts ,  
these 33 patients were combined into' an 'other brands' group. This 
predominance of Lanoxin corresponded with the national sales pattern .  
During 1971 the market shares of digoxin ta b le t  sales were; Lanoxin 61%, 
Boots brand 15%, Kerfoot brand 7%, Evans Medical brand 4%, Cox brand 3%, 
others 10%. (C. Oakley, Department of Health and Social Security:
personal communication, 1972).
The patien t ch aracteris tics  and plasma digoxin concentrations 
found at each d a ily  dosage level are given in Table 3. The patients  
using Lanoxin and other brands were s im ilar  in terms of age, weight 
and blood urea le v e l.  No s t a t i s t ic a l ly  s ig n if ic a n t  differences  
(unpaired t  te s t )  were found in plasma digoxin concentrations o f  those 
taking Lanoxin and those using other brands except for the smallest 
group receiving 0.625 -  0.75mg/day of digoxin (p < 0 .05 ).
DISCUSSION
Three conclusions emerged from these prelim inary studies of 
digoxin b io a v a i la b i l i ty :  (1) some patients (M.P. and L .S .)  showed 
an improvement in th e ir  s ta te  o f d ig i ta l is a t io n  a f te r  a change in 
th e ir  brand of digoxin ta b le t  ( 2 ) there was, o v e ra l l ,  no major 
difference in the b io a v a i la b i l i ty  of Lanoxin and other brands 
(3) grinding some digoxin tab le ts  to a f in e  powder increased th e i r  
absorption.
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Patient M.P. had very low plasma digoxin concentrations when 
taking normal doses of Boots digoxin and was able to to le ra te  the 
very high dosage of 2.0mg/day. I t  had been shown that some patients  
with in te s t in a l malabsorption syndromes could have low plasma digoxin 
concentrations (Heizer e t a l . ,  1971). However a generalised  
malabsorption state  had been excluded in M.P. Craig and Lown (1958) 
had reported a case of a woman whose a t r ia l  f i b r i l l a t i o n  was 
controlled by intravenous digoxin when high oral doses had fa i le d  
-  they suggested that impaired absorption of digoxin might have been 
present but did not investigate  th is  fu r th e r . A case had also been 
previously described in which d ig i ta l is a t io n  was affected by increased 
conversion of digoxin to the card io -in active  metabolite dihydrodigoxigenin  
(Luchi and Gruber, 1968), a m etabolite which would not have been 
detected by the radioimmunoassay. This patient had to lera ted  oral 
digoxin doses o f 2 -  3mg/day but exhibited abnormal behavioural signs 
when on these high doses. An element of impaired b io a v a i la b i l i ty  
cannot, in retrospect, be excluded in Luchi and Gruber's patient and 
indeed,from the urinary digoxin excretion data, appears l i k e ly .  Abnormal 
metabolism was not the explanation in the case of M.P. since her 
elim ination rate  o f digoxin a f te r  an intravenous dose was normal. Her 
digoxin absorption curves a l t e r  the O.Smg doses of Boots digoxin were 
very abnormal compared with results in normal subjects and indicated  
that the defect lay in her digoxin absorption. The increase in her 
steady state  plasma digoxin concentrations a f te r  changing to Lanoxin, 
and la te r  to capsules containing powders o f her Boots ta b le ts ,  indicated  
tha t her capacity to absorb digoxin was not defective . M.P, had been 
started on quinidine therapy in the interval, between using the Boots 
and Lanoxin formulations. Although not considered of importance at
0 4
the tim e, the recent discovery that quinidine increases plasma 
digoxin concentrations by up to 100% (Mannimen and Nyberg, 1981) 
would now indicate that th is  drug in teraction  could account for some 
of the increase in digoxin concentration. I t  would not however 
cause the observed differences in absorption p r o f i le  and did not 
apply to the increase a f te r  changing to the capsules.
Patient L.S. had shown a s ig n if ic a n t  improvement in the 
ven tr ic u la r  rate of his a t r ia l  f i b r i l l a t i o n  a f te r  changing to Lanoxin 
His plasma digoxin concentration increased by 68%. With the number 
of estimations performed, th is  increase ju s t  fa i le d  to reach 
s ta t is t ic a l  s ign if icance , although the plasma digoxin concentrations 
during use of the capsules were s ig n if ic a n t ly  higher than those found 
when he used the Harker-Stagg tablets  in th e ir  o r ig ina l form.
Although in patient M.P, the Boots brand of digoxin ta b le t  had 
been shown to have impaired b io a v a i la b i l i ty  compared with Lanoxin, a 
s im ila r  resu lt  was not found in the other individual patient studies 
when the Boots brand had been used. In animal experiments digoxin 
was absorbed by passive d iffu s io n  through the wall o f the small 
in tes tin e  (Caldwell et a l . ,  1969, Greenberger et a l . ,  1969). I t  
seemed a p o s s ib i l i ty  that some patients had a r e la t iv e ly  small 
capacity for digoxin absorption by v ir tu e  of the length, nature or 
m o t i l i ty  of th e ir  small in tes t in e  and th is  re s tr ic te d  capacity could 
make them more sensitive  than others to any delay in release of  
digoxin from i ts  formulation. This concept had some support from the 
s lig h t  trend in the individual patient studies whereby those with  
lower digoxin levels on th e ir  orig ina l tab lets  showed a greater  
increase a f te r  changing to Lanoxin. Since digoxin was thought to be
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absorbed by simple passive d iffu s io n  i t  seemed most strange that  
M.P. could have such impaired digoxin absorption while able to 
absorb other substances quite  normally. The explanation c le a r ly  
might l i e  with the formulation of her tablets  but standard 
pharmaceutical tests had not shown any formulation abnormality. Her 
ta b le ts ,  and those of L.S.,m et the then current c r i t e r i a  of the 
B rit is h  and American pharmacopoeiae. However when crushing the 
o rig ina l tab lets  of M.P. and L.S. and administering the f in e  powder 
w ith in  a capsule produced more rapid absorption and higher steady 
state  plasma digoxin concentrations, th is  demonstrated that there  
was a large e f fe c t  on absorption by the method of formulation. We 
concluded at th is  time that the formulation e f fe c t  might be due to 
f a i lu r e  of the tab le ts  to d is in tegra te  to fragments o f s u f f ic ie n t ly  
small size fo r  rapid d issolution or to the influence of p a r t ic le  size  
(Shaw, Howard and Hamer, 1972).
The results o f the survey of out-patients had shown that fo r  
patients taking 0.125 -  0.5mg/day of digoxin there was no d ifference  
in the steady state  plasma digoxin concentrations obtained with  
Lanoxin and other brands. There had been a s ig n if ic a n t  d iffe rence  in  
the plasma digoxin concentrations of the out-patients who had been 
using Lanoxin and other brands at a dosage of 0.625 -  0.75mg/day. 
However the number of patients in the ‘ other brands' group was only 3, 
one of whom was L .S . ,  who had attended the c l in ic  fo r  a routine cardiac  
follow-up. n ibb le , Isaacs and Grahame-Smith (1972) published results  
o f absorption curves recorded in four subjects with three brands o f  
digoxin, one of which was Lanoxin. They found no d ifference  in the 
areas under the f iv e  hour curves. This evidence suggested that
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patients l ik e  M.P. and L.S. were uncommon. The few patients who 
were unusually poor absorbers of digoxin would tend to have been 
put on higher doses of digoxin, and th is  might explain the d ifference  
found in the 0.625 - 0,75mg/day group.
I t  was puzzling that the out-patients  had plasma digoxin 
concentrations much lower than those reported by Chamberlain e t a l . ,  
(1970) and Evered, Chapman and Hayter (1970) and tha t so many had a 
concentration below the range of 1 -  2 ng/ml. At a d a i ly  dose of 
Q.5mg/day Chamberlain and colleagues found a mean plasma digoxin  
concentration of 1.5 S.D. 0.4ng/m l, while Evered's group found a 
mean concentration of 1.86 S.D. 1.23ng/ml. I t  was possible that  
our patients were poor in th e ir  compliance with th e ir  prescribed 
dosage. Heart fa i lu re  patients have been found to be r e la t iv e ly  
good at complying with th e ir  digoxin regimes (Brook et a l . ,  1971) 
and patients whom I questioned about compliance maintained that  
they had been very regular in taking th e ir  digoxin ta b le ts .
The reason fo r  the unexpectedly low plasma digoxin concentrations 
with Lanoxin became c lear at the beginning of August 1972. Burroughs 
Wellcome Ltd announced th a t an a lte ra t io n  in the manufacturing process 
of Lanoxin had resulted in a major change in i ts  b io a v a i la b i l i ty  
(Lancet, 1972). I t  was la te r  explained that a combination of in v i t ro  
ta b le t  analyses and resu lts  of absorption tests  with Lanoxin batches 
in four normal subjects had led the company to re a l is e  tha t a change 
in Lanoxin ta b le t  production in la te  1969 had resulted in a decrease 
in b io a v a i la b i l i ty .  I t  was estimated that th is  change caused the 
b io a v a i la b i l i ty  of Lanoxin to be halved (Munro-Faure et a l . ,  1974). 
There had in addition been a return in May 1972 to the orig ina l
0 /
Lanoxin production method which had pertained up to 1969 
(Munro-Faure et a l . ,  1974) i . e .  during the period la te  1969 to 
May 1972 Lanoxin tab le ts  had been markedly reduced in b io a v a i la b i l i ty .  
By the time the changes in Lanoxin b io a v a i la b i l i ty  were noted, 
supplies of the high b io a v a i la b i l i ty  formulation had already been 
d istr ibu ted  to many r e ta i l  pharmacists.
Burroughs Wellcome were faced with the dilemma of having two 
d i f fe re n t  Lanoxin formulations in d is tr ib u t io n  simultaneously.
The company chose to reca ll the batches of lower b io a v a i la b i l i ty  
and wrote to a l l  medical p rac tit io n ers  to explain th e ir  action  
(Figure 6 ) .  I t  is perhaps unfortunate that these announcements and 
newspaper reports (The Times, 1972, Daily  M irro r , 1972) did not re fe r  
to the 1969 change and th is  resulted in some confusion about dosage.
In view of the d ifferences which now existed between Lanoxin and 
other brands (Isaacs e t a l . ,  1972, Shaw et a l . ,  1972) the Committee 
on Safety o f Medicines advised pharmacists to dispense Lanoxin only 
when i t  had been specified on the prescription or when the physician 
had indicated th a t dosage had been reassessed (Pharmaceutical Journal, 
1972a).
Burroughs Wellcome had acted s w if t ly  to a le r t  physicians about 
the change in Lanoxin but the company was uncertain about the exact 
magnitude of the change. Differences between formulations had 
become evident but no pharmacopoeal standard was availab le  to ensure 
consistent b io a v a i la b i l i ty ,  A digoxin b io a v a i la b i l i ty  problem of 
awesome proportions had appeared.
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Wellcome
B u r r O U C lh S  W s i l C O n i B  &  C ô  Medlcal Sales Oivieion taiegramsTabloidOanford
— rFmriti^ nm Tsmpis Hill Oanford Kent DAI SAH talex 896758
laiephone Oanford 234SB
Dear Doctor,
WARNING-DIGOXIN
There is now evidence which suggests that the nominal content of digoxin in a tablet is an 
inadequate indicator of potency. The Committee on the Safety of Medicines is aware of 
this fact
Tablets of different brands, all with a nominal content of 0 25 mg digoxin, may produce 
different therapeutic responses. When the substance is relatively insoluble, as is digoxin, 
the extent to which it is absorbed can be affected considerably by the method of 
fomnulation and method of manufacture of the tablet Until very recently such differences 
were not detectable by assay procedures, but revised quality control procedures have 
enabled us.to manufacmre LANOXIN* tablets with a more predictable clinical response.
Tf Is now apparent how^efi that these tablets, whilst still containing 0-25 mg'digoxin, 
have approximately double the effective potency of earlier batches.
IN THESE CIRCUMSTANCES. IT IS IMPORTANT TO REVIEW THE DOSAGE OF ALL 
PATIENTS RECEIVING LANOXIN TABLETS. This Is of particular Importance with certain 
classes of patient These classes include children, the elderly and others with impaired 
renal function, patients who are also receiving diuretics without potassium 
supplements, and patients receiving doses of 0*5 mg LANOXIN or more daily. IN THESE 
PATIENTS IT MAY BE ADVISABLE TO CONSIDER REDUCING THE DOSE OF 
LANOXIN BY HALF.
The bio-availability of digoxin from LANOXIN tablets may also be greater than that 
from other digoxin tablets, which may in turn differ from each other. Patients stabilised 
on one brand of digoxin could be improperly maintained if subsequently treated with 
another brand.
W e have, in consultation with the Committee on the Safety of Medicines, decided to 
recall all stocks of LANOXIN tablets manufactured before May 1972 and to replace them 
with tablets of the new standard.
Yours faithfully,
BURROUGHS WELLCOME & CO.
Note LANOXIN can be identified by the word Wellcome on one side together with 
a code Number, X3A for the 0 25 mg product and USA for the 0-0625 mg 
Paediatric/Geriatriaptoduct
DISPENSING DOCTORS should examine their stocks of both products and compare 
them with the Batch Numbers below. All stock not bearing one of these numbers should 
be returned to their wholesaler who will replace with material from the new batches.
LANOXIN P.G. Tablets LANOXIN Tablets 0-25 mg
14S6-X 1482-X 1579-X
1531-X 1/1482-X 1538-X
1559-X 14B3-X 1621 -X
1571-X 1/1483-X 1620-X
1594-X 2/1483-X 1623-X
1740-X 1484-X 1666-X
1748-X 14B5-X 1667-X
1749-X 1546-X 1745-X
1750-X 1580-X 1746-X
1767-X •
Subsequent batches of new material will have Batch Numbers greater than those listed. 
‘ Trade Mark 
GS 6602/86
Figure 6 Letter sent to medical p rac tit ion ers  
by Burroughs Wellcome in August 1972.
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CHAPTER 3 
STUDIES ON THE EFFECT OF THE CHANGE 
IN THE MANUFACTURING TECHNIQUE OF LANOXIN
INTRODUCTION
A fter  the announcement that the Lanoxin brand o f digoxin ta b le t  
had undergone an unexpected increase in b io a v a i la b i l i ty  in May 1972,
I wanted to establish how the steady state  plasma digoxin concentrations 
in patients using th is  newer formulation ('newer Lanoxin') compared 
with those obtained with the 'o lder  Lanoxin' manufactured ju s t  before 
the change. I t  would also c le a r ly  be of in te re s t  to compare results  
from these formulations with Lanoxin produced p r io r  to the i n i t i a l  
a lte ra t io n  in manufacturing technique in 1969. Fortunately steady 
state  plasma digoxin concentrations in cardiac ou t-patien ts  at 
St. Bartholomew's Hospital had been recorded early  in  1969 by 
Chamberlain e t a l . ,  (1970). The patients in my survey of out-patients  
formed a group who had been using ' o lder Lanoxin'. Since an accurate 
estimation of the b io a v a i la b i l i ty  of the newer Lanoxin was not known, 
at th is  time, I f e l t  th a t  a randomised crossover study at fixed dosage 
was not ju s t i f i a b le  because of the r is k  of inducing d ig i t a l is  to x ic i ty .  
The patients who received the newer Lanoxin were therefore collected in 
two ways:- ( 1 ) a group of out-patients  l iv in g  near the hospital would 
be changed from the older Lanoxin to the newer Lanoxin. Dosage would 
be reduced i f  previously they had been taking an unusually high 
dose of digoxin r e la t iv e  to th e ir  weight and renal function.
(2) Patients in the medical and surgical wards o f S t. Bartholomew's 
Hospital who were receiving digoxin would be put on the newer Lanoxin 
form ulation, with dosage adjusted, when necessary, in a s im ila r  manner.
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In order to observe the peak plasma digoxin concentrations 
a f te r  oral doses of older and newer Lanoxin, absorption curves 
were measured in myself and my colleague, Michael Howard.
I obtained samples o f tab le ts  from a range of companies fo r  
in v i t ro  testing to investigate  how newer Lanoxin compared with  
digoxin tab le ts  o f other manufacturers.
METHODS
Patients
a) Out-patients
One hundred and eleven patients had now been surveyed at the 
ou t-p atien t c l in ic .  S ixty  had used Lanoxin and 51 had used other 
brands. In 2 cases, one from each group, a digoxin dose had been taken 
immediately before the c l in ic  v i s i t  and i t  was not possible to c o lle c t  
a blood sample at over 6 hours a f te r  th e ir  preceding dose and these 
patients were excluded. Three patients had taken th e ir  la s t  dose 
1 0 - 1 8  hours before blood sampling, with the in terva l being 6 - 1 0  hours 
in the remainder. The brand o f ta b le t  was id e n t if ie d  as described in  
Chapter 2.
To compare the plasma digoxin concentrations of these patients  
with the results obtained by Chamberlain and colleagues in early  1969 
i t  was necessary to r e s t r ic t  the analysis to patients with normal or 
near normal renal function as Chamberlain had studied only patients  
with good renal function. T h ir ty  patients with a blood urea greater  
than 40mg/100ml were therefore excluded. Five patients taking  
0.125mg/day of digoxin and 1 patient taking Img/day were also excluded 
as Chamberlain et a l . ,  had not included patients a t these dosage 
le v e ls . Of the 73 patients remaining 38 had used the older Lanoxin 
and 35 had used other brands.
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Twenty of the ou t-patien ts  with good renal function had plasma 
digoxin concentrations measured a f te r  changing to newer Lanoxin 
at the same dosage. Eight of these 20 patients had previously used 
a brand other than Lanoxin; they were given a supply of newer Lanoxin 
(batch 1579X) and had th e ir  plasma digoxin concentration measured one 
week la te r  at 6 -  10 hours a f te r  th e ir  la s t  dose. Twelve of the 
20 patients had previously been using Lanoxin: they were given f i r s t  
a supply of older Lanoxin (batch 0953X) and had a blood sample taken 
for plasma digoxin concentration estimation one week la te r .  They were 
then changed to newer Lanoxin (batch 1579X) at the same dosage and returned 
for measurement of digoxin concentration a f te r  one week,
b) In -pa tien ts
I carried out a review of a l l  the patients in the medical and 
surgical wards of the hospital on 8 th August 1971, and recorded 
d e ta ils  of those on digoxin treatment. Three d i f fe re n t  batches of 
Lanoxin were in use in  the wards on that date -  0953X (older Lanoxin) 
and 1483X and 1579X (both newer Lanoxin). The b o tt le  of digoxin in 
each ward had the batch number printed on its  label and the date of 
supply of the b o tt le  to the ward was availab le  from the pharmacy 
records. I t  was therefore possible to establish which formulation had 
been used by each in -p a t ie n t  during the preceding week. With the 
consultants' permission, each patien t was changed to an appropriate  
dose of newer Lanoxin. Twelve in -patien ts  on digoxin had a blood urea 
of less than 40mg/100ml. Five had already been receiving the newer 
Lanoxin fo r  at leas t one week - a blood sample for plasma digoxin 
estimation was taken 6 - 1 2  hours a f te r  th e ir  preceding dose. Seven 
had been receiving older Lanoxin fo r  a week or more. Measurement of  
th e ir  s tate  steady plasma digoxin concentration was made pr io r  to
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changing th e ir  therapy to newer Lanoxin (batch 1579X) a t the same 
dosage. Plasma digoxin concentration was measured again a f te r  one 
week on the newer formulation.
All of the out-patients  and in -pa tien ts  had a 30 second lead I I  
rhythm s tr ip  recorded at the time of each blood sampling.
Lanoxin tablets
The results of pharmaceutical tests on tab le ts  of batch 1579X 
newer Lanoxin were provided fo r  me by H. Greer of the Pharmaceutical 
Development Department, The Wellcome Foundation Ltd, D artford , Kent:- 
Mean ta b le t  weight : 112mg S.D. I.im g (sample o f 20 ta b le ts )  
Content ; bulk assay : 101.2% of stated dose
indiv idual ta b le t  assay : 100.8% S.D. 1.9%
(sample of 20 ta b le ts )
Tablet hardness (Monsanto Tester) ; 3 -  4Kg 
D isintegration time : 2 minutes
The dissolution te s t  results of th is  batch, and of batch 0953X 
(o lder) Lanoxin, is included in the results section.
D isintegration and dissolution rate tests
Batches of digoxin tab lets  were obtained from 15 d i f fe re n t  
manufacturers. This l i s t  o f manufacturers had been compiled during 
brand id e n t if ic a t io n  in the ou t-p atien t survey. The d is in tegra tion  
and dissolution rate  of these ta b le ts ,  and of batches 1579X (newer) 
Lanoxin and 0953X (o lder) Lanoxin were measured by Mr. A.C. Caws 
of the Central Analytical Laboratories (Chemical) of The Wellcome 
Foundation Ltd. The d is in tegra tion  rate  method was that of the B rit is h  
Pharmacopoeia (1968). The dissolution ra te  method was based on that  
of the United States Pharmacopeia and has been described in d e ta il  by 
Caws, Jenkins and McCrerie (1974). Six tab lets  of 0.25mg strength
73
were placed in a stainless steel basket set to rotate  at 120rpm in 
500ml of 0.6% hydrochloric acid. Samples of the f lu id  were removed 
at in terva ls  for measurement of digoxin concentration by the 
f lu o r im etr ic  method.
Absorption curves
Plasma digoxin concentrations were measured from 0 - 8  hours 
a f te r  0.5mg oral doses of digoxin in two normal subjects -  MRH ( 6 8 Kg) 
and TRDS (65Kg). The subjects had fasted overnight p r io r  to taking  
the dose along with 50ml of water. Two tablets formations were 
used - older Lanoxin of batch 0953X and newer Lanoxin of batch 1579X. 
A liq u id  formulation of Lanoxin was also taken o ra l ly  as a O.Smg dose 
of Lanoxin solution ( lo t  80601) marketed fo r  parenteral in je c t io n .
The doses were given in randomised order and at least 3 weeks elapsed 
between doses. The subjects were ambulant a f te r  the doses were taken,
RESULTS
The steady state  plasma digoxin concentrations recorded in the 
38 out-patients using older Lanoxin and the 35 out-patients using 
other brands are given in Table 4. This Table also gives the 
digoxin concentration results of the 32 in -patien ts  and out-patients  
who had received newer Lanoxin. The Table includes the digoxin 
concentrations recorded by Chamberlain et a l . ,  (1970) in s im ilar  
patients in 1969, p rio r to the i n i t i a l  change in Lanoxin manufacturing 
technique. Older Lanoxin and the other brands produced s im ilar  
plasma digoxin concentrations (p > 0.05 for a l l  dosage groups. 
Student's paired t  t e s t ) .  Newer Lanoxin gave s ig n if ic a n t ly  higher 
plasma digoxin concentrations than older Lanoxin : 86% higher at 
a dosage of 0.25 - 0.37mg/day (p < 0 .0 1 ) ,  69% higher at a dosage of 
0.5mg/day (p < 0,01) and 74% higher fo r  a dosage of 0.625 -  0.75mg/day
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(p < 0 .0 5 ) .  Digoxin concentrations with newer Lanoxin were very s im ila r  
to those found with Lanoxin in 1969 by Chamberlain e t a l .  The 
differences between these formulations are i l lu s t r a te d  in Figure 7.
The results found in the 19 patients who received both older 
and newer Lanoxin are given in Table 5. The mean plasma digoxin 
concentration when using older Lanoxin was 0.86ng/ml (S.D. 0.28) which 
increased by 70% to 1 .46ng/ml (S.D. 0,54) a f te r  the change to newer 
Lanoxin. This d ifference in plasma digoxin concentration was 
s t a t i s t ic a l ly  s ig n if ic a n t  (p < 0 .01 , paired t  t e s t ) .  The increase 
recorded in individual subjects varied considerably. In the 0.5mg/day 
group the increase varied from 0% to 317%.
None o f these patients developed d ig i t a l is  to x ic i ty  as a resu lt  
of changing from older to newer Lanoxin. Plasma digoxin concentrations 
found in the out-patients survey had tended to be below the range of 
1 - 2ng/ml (Figure 8 ) and 75 o f the 109 patients (69%) had a digoxin 
concentration o f less than Ing/ml, There was also a high incidence of 
poorly controlled a t r ia l  f i b r i l l a t i o n .  Table 6 shows the ve n tr icu la r  
rates recorded a t rest in the 74 patients who had a t r ia l  f i b r i l l a t i o n .
In 51% the ve n tr ic u la r  ra te  was greater than 90 beats per minute. 
Fourteen patients (19%) had been prescribed a beta-adrenoreceptor 
blocking drug to help in the control o f heart ra te . The incidence of 
d ig i ta l is  to x ic i ty  was also very low. Of the 109 p a tien ts , 14 had, at 
th e ir  f i r s t  ou t-p a tien t in terv iew , an arrhythmia c la s s if ie d  as 
possibly due to d ig i t a l is  to x ic i ty  according to the c r i t e r ia  of 
S e lle r  et a l . ,  (1971). To determine i f  the arrhythmia was due to 
to x ic i ty  or to heart disease each of these 14 patients had fu rth e r  
observations a f te r  th e ir  digoxin dosage had been e ith e r  reduced or 
increased. The decision to reduce or increase digoxin dose was based
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on the plasma digoxin concentration and the dosage used. The 
arrhythmias were:- multiform v e n tr ic u la r  ectopic beats at more 
than 5 per minute -  7 patients; unifocal v e n tr ic u la r  ectopic beats 
of more than 5 per minute -  4 patients; supraventricular ectopic 
beats at more than 5 per minute -  2 patients; nodal rhythm - 1 pa tie n t.  
The patien t with a chronic nodal focus had th is  arrhythmia pers ist  
even a f te r  digoxin was stopped. Five of the patients with ectopic  
beats had th e ir  ectopy cease or reduce in frequency when digoxin 
dosage was increased. In 7 patients the ectopy persisted despite 
reduction or cessation o f digoxin dosage. I t  was concluded therefore  
tha t in 12 of these 13 patients the arrhythmias were due to th e ir  
heart disease rather than to d ig i t a l is  to x ic i ty .  Only one patien t had 
probable to x ic i ty  : in  her case m ultifocal v e n tr ic u la r  ectopic beats 
progressively increased in frequency as digoxin dosage and plasma 
digoxin concentrations increased, culminating in coupled ectopic beats 
at a plasma digoxin level of 2.5ng/ml.
Tablet d issolution rates
The results of the d issolution ra te  tests are given in Table 7, 
There was a wide va r ia t io n  between brands. The percentage of the stated  
dose in solution by 60 minutes varied from 33 to 118%.
Absorption curves with older and newer Lanoxin
The plasma digoxin concentrations recorded in the 2 normal 
subjects a f te r  O.Smg oral doses o f older Lanoxin, newer Lanoxin and 
Lanoxin solution are shown in Figure 9. Peak plasma concentrations 
a f te r  the solution (2.1 and 3,4ng/ml) were s im ilar  to those a f te r  newer 
Lanoxin (2 ,3  and 2.7ng/ml) and considerably higher than the peak 
concentrations a f te r  o lder Lanoxin (0 .9  and 0.9ng/m l).
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Figure 9 Plasma digoxin concentrations recorded in normal 
subjects M.H.R. and T.R.D.S. a f te r  O.Smg oral 
doses of older Lanoxin (open c i r c le s ) ,  newer 
Lanoxin (closed c irc le s )  and Lanoxin solution  
(crosses).
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DISCUSSION
The object of th is  part of my studies had been to assess how 
the b io a v a i la b i l i ty  of newer Lanoxin compared with ( 1 ) 'o lder Lanoxin' 
and (2) Lanoxin produced before the f i r s t  manufacturing change of 
1969. I t  was necessary to do th is  in a way which would protect  
patients from developing d ig i t a l is  to x ic i ty .  I t  was also important 
to be able to obtain results quickly as we were faced at tha t time 
with the c l in ic a l  problem of modifying the digoxin therapy of large  
numbers of cardiac patients as a consequence o f the la te s t  Lanoxin 
a lte ra t io n . These objectives seemed to be met best by measuring the 
steady state  plasma digoxin concentrations in a fu r th e r  group of 
patients rather than by undertaking a series of single dose 
absorption-curve studies in normal people, although such studies would 
c le a r ly  also be required before the b io a v a i la b i l i ty  of Lanoxin was 
f u l ly  characterised. I chose the method which I f e l t  suited best the 
objectives in view and the f a c i l i t i e s  availab le : the hospital provided 
contact with many patients on digoxin treatment but had very lim ited  
access to normal subjects able to take part in prolonged b io a v a i la b i l i ty  
studies. This was a policy which was to be followed in my subsequent 
b io a v a i la b i l i ty  experiments.
The patients who received both older Lanoxin and newer Lanoxin 
at the same nominal dose had shown a mean increase of 70% in plasma 
digoxin concentration a f te r  changing to the newer formulation. Differences  
of s im ila r  magnitude were found at each dosage level in the patient  
survey groups. These results confirmed that newer Lanoxin gave 
considerably greater absorption of digoxin, but the increase was 
s l ig h t ly  less than the two-fold d ifference i n i t i a l l y  estimated by 
Burroughs Wellcome. Falch, Teien and Bjerkelund (1973) reported results
8 4
obtained with older and newer Lanoxin in patients and normal 
volunteers. The newer Lanoxin gave much higher peak plasma digoxin 
concentrations during the absorptive phase and urinary excretion o f  
digoxin was 40% greater w ith the newer formulation. However they 
found only a 10% increase in steady s ta te  concentrations in a group of 
14 patients . In th is  group the older Lanoxin had given a r e la t iv e ly  
high mean plasma digoxin concentration of 0.94ng/ml for a dose of 
0.25mg/day. Patients at a higher dosage were not included and i t  
was not c lear i f  the.authors had selected fo r  the t r i a l  only patients  
on a low dosage, who may have had a good absorptive capacity fo r  slowly  
released digoxin. W hiting, Rodger and Sumner (1972) compared a group 
of 30 patients on 0.5mg/day of o lder Lanoxin with a group of 24 patients  
taking 0.25mg/day of newer Lanoxin. Taking in to  account the change in 
dosage, steady s ta te  plasma digoxin concentrations indicated tha t newer 
Lanoxin had 58% greater b io a v a i la b i l i t y .  An average increase of Lanoxin 
b io a v a i la b i l i ty  of 178% was found by Stewart and Simpson (1972), using 
steady state  measurements in  an undefined population. Manninen, O ja la ,  
and Reissell (1972) noted a 28% increase in steady state  digoxin 
concentration in a small group of 8 patien ts . In a single dose study 
in normal volunteers, Johnson et a l . ,  (1973) found th a t the area 
under the 50 hour absorption curve was 84% greater with newer Lanoxin 
compared with o lder Lanoxin, and 4 day urinary excretion was 100% higher.
The d ifference  in magnitude of change between studies must r e f le c t  a 
number of factors -  design of the study, subject population and the p a r t ic u la r  
batches o f older Lanoxin used (the d issolution rate  o f batches o f older  
Lanoxin varied from 43% - 64%, according to Munro-Faure e t a l . ,  (1974). The 
mean increase found in these reports was 73%. For individual patients the
85
increase in Lanoxin b io a v a i la b i l i ty  could be as great as s e ve ra l- fo ld .
In this circumstance there would be a considerable r is k  o f to x ic i ty  
i f  the patient changed from a low .to a high b io a v a i la b i l i ty  digoxin 
formulation at a dosage chosen to give adequate therapeutic a f fe c t  
during use of the low b io a v a i la b i l i ty  product. Fortunately for most 
patien ts , physicians seemed to have maintained a conservative approach 
to digoxin dosage during 1969 -  1972 and un derd ig ita l isa tion  with 
lo w -b io a v a i la b i l i ty  tab lets  was the commoner phenomenon. This was 
i l lu s t r a te d  by the poor control of a t r ia l  f i b r i l l a t i o n  and the lack of  
to x ic i ty  seen in the o u t-p a tien t survey.
Reports of differences in b io a v a i la b i l i ty  of digoxin ta b le t  
brands were subsequently reported from many countries: e .g . Finland 
(Manninen et a l . ,  1971, K arja la inen , Ojala and R e is se ll ,  1974 
Li sal 0 & Ruikka, 1974), Sweden (Redfors et a l . ,  1973, Nyberg et a l . ,
1977), Denmark (Steiness, Christensen and Johansen, 1973),
Switzerland (Beveridge et a l . ,  1975) and A ustra lia  (McCredie e t a l . ,  1973)
The newer Lanoxin produced in B rita in  was subsequently shown to 
have the same b io a v a i la b i l i ty  as a l iq u id  formulation. Johnson and Lader, 
(1974) found tha t the area under the 80 hour absorption curve and the 
10 day urinary digoxin excretion were s im ila r  for s ingle doses of newer 
Lanoxin and digoxin dissolved in an alcoholic solution, Manninen,
Reissell and Ojala (1976) also found equivalent steady state  plasma 
digoxin concentrations and urinary digoxin excretion at steady state  
during use of these formulations.
Lanoxin fo r  the American market is produced w ith in  the United 
States. The American formulation did not undergo any changes in 
production technique during 1969 - 1972. However U.S. Lanoxin had a 
separate production technique and did not correspond exactly to e ith er
older or newer B r it is h  Lanoxin. B io a v a i la b i l i ty  studies in the 
United States subsequently established two points (1) differences in 
b io a v a i la b i l i ty  existed between U.S. Lanoxin and other brands marketed 
in that country. (2 ) Absorption from U.S. Lanoxin was s ig n if ic a n t ly  
less than from a digoxin solu tion .
In th e ir  i n i t i a l  re p o rt , Lindenbaum e t a l . ,  (1971) had shown 
marked differences in the area under the 5 hour absorption curve fo r  
4 U.S. digoxin brands. This indicated differences in the absorption 
rate  but not necessarily in the extent of absorption (Sorby and Tozer, 
1973). Lindenbaum's group did however la te r  show differences in 
24 hour urinary excretion of digoxin for these formulations and 
24 hour excretion data has been found to corre la te  well with 6 day 
excretion results (Greenblatt e t a l . ,  1974). Wagner et a l . ,  (1973) 
showed tha t a U.S. digoxin ta b le t  formulation which met a l l  the U.S. 
Pharmacopeia standards had almost h a lf  the b io a v a i la b i l i ty  o f U.S. 
Lanoxin, as assessed by the area under the 96 hour absorption curves : 
th is  d ifference persisted even when the data was re interpreted a f te r  
extrapolation of the area-under-the-curve plots to in f in i t y  (Wagner 
and Ayres, 1977). Two-fold v a ria t io n  in steady state  digoxin levels  
were recorded by Lindenbaum e t a l . ,  (1973) in a study of 5 U.S. 
digoxin brands. P re ib isz , Butler and Lindenbaum (1974) used both 
single dose and steady s ta te  plasma and urine concentration methods 
to compare 3 U.S. brands. The single dose studies gave greater  
differences than the steady state  measurements, but even in the 
l a t t e r  va ria t io n  of nearly two-fold was found. They observed marked 
differences in b io a v a i la b i l i ty  between d i f fe re n t  batches from the 
same manufacturer, as was also found by Lindenbaum (1975). In addition  
to differences in steady s ta te , absorption curve and cumulative
0 /
urinary digoxin excretion with 2 U.S. brands, Fleckenstein, Kroening 
and Weintrant (1974) recorded p a ra lle l  changes in systo lic  time 
in te rv a ls ,  re f le c t in g  d i f fe r e n t  degrees of pharmacologic e f fe c t .
The submaximal b io a v a i la b i l i ty  of U.S. Lanoxin has been 
documented by a number o f studies. Huffman and Azarnoff (1972) 
used 10 day cumulative urinary excretion data and found U.S. Lanoxin 
gave 75% absorption compared with a solu tion . Vieweg and Sode (1973) 
suggested that U.S. Lanoxin and a solution had equivalent b io a v a i la b i l i ty  
but th e ir  data is in s u f f ic ie n t  fo r  th is  conclusion. U.S. Lanoxin 
achieved 84% of the  b io a v a i la b i l i ty  of a digoxin e x i l i r  in the single dose 
studies by Greenblatt e t a l . ,  (1973). In a steady state  experiment which 
included chronic intravenous dosing Huffman, Manion and Azarnoff (1974) 
found the absolute b io a v a i la b i l i ty  of digoxin solution to be 77% while  
tha t of U.S. Lanoxin was 62%. Lloyd e t a l . ,  (1978) also showed th a t U.S. 
Lanoxin tab lets  were incompletely absorbed, using both single dose 
and steady state  assessments.
In the United Kingdom the results in our ou t-p atien t survey 
confirmed that newer Lanoxin had much higher b io a v a i la b i l i ty  than many 
o f the other commonly used brands (Shaw, Howard and Hamer, 1974).
The dissolution ra te  results on the 15 other brands also indicated tha t  
these brands d if fe re d  from newer Lanoxin. A s im ila r  spectrum of  
dissolution rates in B r it is h  digoxin tablets  was found by Beckett 
and Cowan (1973) and Fraser, Leach and Poston (1974).
These studies had c le a r ly  demonstrated that a serious problem 
existed with digoxin ta b le t  b io a v a i la b i l i ty .  I t  remained to find a 
way to ensure equivalent and consistent b io a v a i la b i l i ty  fo r  digoxin 
tab le ts  from a l l  manufacturers.
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CHAPTER 4
THERAPEUTIC NON-EQUIVALENCE OF DIGOXIN TABLETS IN THE 
UNITED KINGDOM AND ITS CORRELATION WITH TABLET DISSOLUTION RATE
INTRODUCTION
The experience gained from the study of older and newer Lanoxin 
and the data on the d issolution rates of other brands made i t  feas ib le  
to carry out a t r i a l  to compare d i f fe re n t  brands o f digoxin tab lets  at 
fixed dosage. One problem in th is  type o f study is the p o s s ib i l i ty  of 
causing an unacceptable degree of to x ic i ty  or loss o f therapeutic e f fe c t .  
However I had contact now with a large number o f patients whose 
severity  of heart disease, arrhythmia sta tus , renal function and steady 
digoxin plasma digoxin concentrations were known. I t  therefore appeared 
eth ica l to enter these patients in to a b io a v a i la b i l i ty  t r i a l  at a 
dosage which one could expect with confidence would not cause serious 
to x ic i ty  nor d e te r io ra tion  of th e ir  c l in ic a l  s ta te . Now that the 
dissolution rates were known fo r  a large number of digoxin ta b le t  brands, 
i t  was possible to choose a selection of brands which would represent a 
f u l l  range of d issolution rates.
The design of a t r i a l  to compare the b io a v a i la b i l i ty  of digoxin 
brands had to overcome one fu rth e r  problem. I t  would be desirable to 
compare the largest number of brands possible, but as most of the 
patients using digoxin were working or had commitments to th e ir  home, 
i t  was necessary to l im i t  th e ir  hospital attendances fo r the t r i a l  to a 
degree which was acceptable to the pa tien t. I t  was decided therefore  
to d iv ide  the pa tien t population into two groups, each of which would 
receive four brands o f digoxin ta b le t .  The newer Lanoxin would be 
used by both groups, so th a t the data of the two groups could be 
combi ned.
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The use of steady state  plasma digoxin concentrations was chosen 
as the index of b io a v a i la b i l i ty  as i t  appeared the most appropriate  
for  the study o f a large number o f cardiac patients .
METHODS
Patients
Two groups, each of 20 subjects, were chosen from the 111 patients  
in the ou t-p a tien t survey. These 40 patients were those who had 
attended the c l in ic  most recently  and who lived s u f f ic ie n t ly  close to 
the hospital to be able to undertake additional v is i t s .  A few patients  
who had had m ultip le  attendances fo r  previous digoxin b io a v a i la b i l i ty  
studies were not included. Each pa tien t had agreed to take part a f te r  
a fu l l  explanation o f the t r i a l  and i ts  procedures. The characteris tics  
of the patients are given in Tables 8 and 9, • Other medication remained 
unchanged throughout the t r i a l .  Two patients did not complete the 
t r i a l  period. Patient 1 o f  group 1 developed cho lecystit is  and was 
admitted to hospita l. Patient 20 of group 2 was hospitalised because 
of myocardial in fa rc t io n .
In group 1 there were 14 females and 5 males; group 2 had 
15 females and 4 males,
Digoxin tab lets
Seven brands of digoxin tablets  were used in the t r i a l .
They were:- Group 1 Newer Lanoxin (batch 1579X)
N a t iv e l le  (batch 369)
Boots (batch 12N)
Older Lanoxin (batch 0953X)
Group 2 Newer Lanoxin (batch 1579X)
Macarthys (batch S2435)
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Oppenheimer (batch 30005)
Cox (batch 212051 )
The manufacturers had supplied, in confidence, the excipient  
substances of th e ir  tab le ts  and an o u tl in e  of th e ir  manufacturing 
process. A ll brands met the B r it is h  Pharmacopoeia (1968) requirements 
fo r  digoxin content.
D is integration rate  tests
These were carried out by K. Raymond at the Department of  
Pharmaceutics, School of Pharmacy, University  of London, WC1 using the 
method o f the B rit is h  Pharmacopoeia (1968).
Dissolution rate  tests
These were also carried out by K. Raymond. The method of the 
United States Pharmacopoeia (1970) was employed, using 600ml of 
d is t i l le d  water (Raymond, Shotton and P a te l, 1974). The basket was 
rotated at 120 revolutions per minute. Samples for digoxin assay were 
removed at 15, 30, 45, 60, 90 and 120 minutes. A fte r  f i l t e r in g  of the 
f lu id  sample through a M il l ip o re  f i l t e r  (0.45pm pore s ize ) digoxin was 
measured by the f lu o r im e tr ic  method of Jensen (1953). Six tab lets  were 
used fo r  each measurement o f dissolution rate  and for each brand the 
dissolution rate  te s t  was performed on 3 separate occasions. The brands 
were coded and th e ir  exact id e n t ity  was not known by K. Raymond a t the 
time of performing the dissolution rate  te s ts , although ta b le t  markings 
prevented complete masking of brand id e n t i ty .
Procedures
The patients were given coded bottles containing 50 ta b le ts . The 
brands were used in randomised order. The code was retained by the 
pharmacy department and was released only a f te r  the dissolution rate and 
plasma digoxin concentration estimations had been completed. Each
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patient took th e ir  digoxin dose in the evening to allow s u f f ic ie n t  
time between the la s t  dose and the blood sample, which was taken on 
the following morning. Patients remained on each brand for a 2 week 
period at the end of which they attended fo r  c l in ic a l  examination, 
a venous blood sample fo r  plasma digoxin concentration and recording 
o f a 30 second electrocardiogram rhythm s t r ip .  A count o f  tablets  
remaining in the b o tt le  was used to assess compliance with the dosage.
Blood samples were always taken at leas t 10 hours a f te r  the preceding 
dose. The average in te rv a l from the dose was 13 hours (range 10 -  17) 
and varied l i t t l e  fo r  indiv idual patients .
RESULTS
The digoxin dosages and plasma digoxin concentrations recorded 
in the group 1 patients are in Table 10 and those of the group 2 patients  
are in Table 11, The mean digoxin dose used by the group 1 patients  
was 0.34mg/day (S.D. 0 .12) and the mean dose of group 2 patients was
0.36mg/day (S.D. 0 .2 0 ) ,  The mean plasma digoxin concentrations found 
with each brand are given in Table 12. Analysis of variance showed that  
the differences w ithin each group were s t a t i s t ic a l ly  s ig n if ic a n t  (p < 0 . 0 1 )
The ta b le t  counts showed th a t compliance with the dosage 
instructions had been good. The discrepancy between the number of 
tab le ts  found to be remaining and the number expected to remain a f te r  
correct dosing was less than 3% o f  the to ta l amount of tab le ts  prescribed.
The d is in tegration  and dissolution rate  tes t results are l is te d  
in Table 13. The dissolution ra te  p ro fi le s  are i l lu s t r a te d  in Figure 10. 
The reproducabi1i t y  o f the dissolution rate  measurements is shown in 
Table 14. Correlation coe ffic ien ts  were calculated fo r  the percentage 
o f stated dose in solution at each time in terva l and the mean plasma
94
CÛ
t/3
0)
"ôj
>
Z
O 4->
ta
H - z
C
Cd
\— e
Z
LU 03
(_) LO C toZ  Z 4->
o  o O
C_) 1—1 tn O
t— c 00
z  < o
1—1 _ J
X  =3 4-i
o  z ftj
CD Cd L .
HH o 4-) C
o  Ll C
0» X
H— u o
s  LU c c
LO - J o ta
«=C ÛQ o
c c .
tu
Q Z X TD
Z  t-H o
< c  X 03 O
o
LU CD XJ
LO w  
O  Q ta
Q E
'vt* to C
Z ta
t - H  L l X
X  o CL o
o c:
CD LU la
w  t/3 _u
Q 3  
>- CD
S-
<u
— I Z s
t—t  t - H tu
Q  ZD Q
t r ,  S
LU O  h-1 O 
h - LU 
<  Cd 
CL
>» <u ca 
to -o 
o
Q  03
OLnC0C0 «0' 00'*“ 00 03>:d-C0f— L0r'^03L003CJ3L0
• • •  # A « » •  # A e.T— CU o  f-  T— eu T— eu cu T— eu C3 T—' Q
C0Ot0CT3<a-CUOI^03 03 03CnC0r',t000t003CU 
T— T—CU CJ T— T— co  e u  CD CD *f”  ^D CO T— CU CO
U D r —< 3 - t O C O O C O L O C O O C O C U T — LO«! f * a* LC )C J3C U  
O  v—v—Q  0 ^ 0 0 0 » — O C U  'T— O  O  T— CD CD t—
O C 0 C T 3 C U t 0 0 3 C U h v . C U C U O L 0 L f > C 0  CO CO 00  03  CO 
r— T— f —T— CO ' CD T— V— eu ^D V— co CD
LCÏ un  U3 L f3L f) L D U n  L O L D  L D L O L O
C U L O C U U D C U L n C U C U L O C U C U L O L D C U C U L O C U C U C U
O O C D C D O O O O O O O O O O O C O O O O
CL
CO
§ +Jc<u
-(3
fCJ
CL
cuco<±Lntor-''00O3C3 CUOO«a*Lr3tDf^C0030
K— T— T— T— T— %— <r- T—• cu
95
CQ
<  C£L Q =)Q
Q 
in  Lu
ë g
Ü J  O
I— » of— LU<  ûi 
a .
CM
CL=3
§
ID
CO
X
in _ c
z +J r~x X
o L.
n3 O  C3 C3
1— (J
<s: fO
cc s :
1— E
z
LU c n
o  m c
2 :  2 :
o  o L .
O  w CO OJ
t— c E
2 :  < c o
h—( _ J (U I X  «d*
X  3 3 4-» _c:
o  z n3 c: o  o
CD OC S- <u
w  O ■M o .
O  Lu C
OJ
Q .
O
S t
u
c
OO — 1 o
<  CO o
— 1 c
O . i— c X I X  x;}- CO
o
Q  2 X CJ) O  O o
Z  hh o
<  X cn
o
LxJ CD T 3
m  1—«
O  Q fO c
O s« ït CO X
z (D o
t—4 Lu c
X  o Q . fO X  CO C3
o — J
CD LU o  o
1—4 CO L.
O  =3 (U
s
> -  CD OJ
- J  Z z
O
coac^ocor^r^cocoixj 
O  T— t — c— T— < 3  C 5 O  O  O
C O ^ < i - V O C D r ^ ' = 3 ' O C M C O  
^ 3  T — «T— O  C3  ^ 3  X— X— ^ 3
o  CO LO CO 
a  a  c3 C3
r^x^^cOLOo-cMr^cocOLncnx—cocnoococO':TLo 
# # # » # # # « # # «  • • » •  
— X— O O O O O x — 0 C3 0 0 0 0 C3
r~s CO o o  CTï  CM  
X—  C 3  X—
CO 
C 3  C 3
> >  
O) fO 
CO X Î
O s
+Jco
cnLOLOLn LOcoLOLn LOLOLncncM
C M C M C M L O C n L O C M C M C M C M C O L O L O L n C M C M C M C M x — t
0 0 0 C3 0 C3 C3 0 0 C3 X— C3 C3 C D 0 C3 C3 0 0
as
Q_
CMoox^cncor^oocTiCD C M o - ) ' ; f i r ) c o r ~ x C O ( T » c o
96
CM
ÜJ
CO<c
CO<c
X
S
LuO
in
g
3
CO
00
gt—
int—
3
g=)
2
Q
CO
+1
00zo
cQC
8
X
§
Q
<
<
CL
z
o
K-
<c
DC
I—Z
LU
O
z
o
o
z
< cLU on X
s: X CM
o
LU c o o
Z rO X
(— —1 +1 o ’ o +1
Q X CD X
Lu s, LO '
O OO <u cn X
CU TDLU =) +1 o O
g  o O
f=C DC in
1— CD c
Z fO
LU |_ 0)
EDC o CO
W H- <r 0» CMQ. E
_  Lu to o •r~ O*=C Q 4-) O)
E O +1 CO z 4*1 X—
i n  (/) O X c 00
<  1- O) z CM 0) CMz c O Cl 00
R LU CLLU H-* O o
OO h- in
pO < c
LU Q_ o
DC
Q- LU +J L£0X  3= n3 X OO
LU |_ S- OJ m
4-Ï X oz  z C o z
O H-* OJ OJ 4-> 4*1 X—1—1 u > +1 CM S-. on
1— z c: cn nJ CM *-—"
■=C w o 4-3 o  —- U cn
z  X o fO CM fO
!z o z s: o2: z c
LU <
CD _j X
z o
O QC cn
O LU_  z T3 c cz  LU CM
<  z rC X un X OOLU E o o
S  z to c O '—" c CDn3 rtJ o to CD1 É _J +1 o _J 4-1 C3
pC z Z
t— c. o c.
Q OJ OO CU CD
00 z 3 3w ID 0) OJ
>  o z z4-H Lu
CD
OO
00 CM
LU ■CJ *oZ c CL c Q.
H— rtj 3 rtJ 3Z S- O c. OLU CÛ S- m s-DC CD CD
<
D_
Z
LU
Z
z
CD
Lu
LU
Z
1—
97
o  I—'
in  X
4—t <C
O
CM
CDO COX LOLO OLO CMLO LO CO00
z  z
LU LU
OO
LU
z
h -  Z  00 
*=c in
Z  Z  LU
CD =3: z
LU
OO
in  z
LU 
I— LU CD 
<C Z  Z  
Z  e t: o
CD
z  OO 
O  h - z
I—I Z  t—I 
t—  LU X  
33 h~4 O  
—I CD CD
O  t-H h—I
00 Z  O0 0  z
I—4 LU e t
z  3o  z
I— LUet m
g i
zz
ë s Z c
• o  z (0
Z  CD E e t O COz  z c O X LO
z  z  z o oÛÛ 1—t 1—) cneC X 3: z
z  o 3
CD
Z  f-H £3 o
t-H Q  Z in
X  z c
o  z  o CU c
CD O  Z Z E O X X
rO O LO z
O  z  Z i - CU o
CD Z CO LOZ  e t  > c o
o  z  z o • a
Z  Z
OO Z z ■o
Z  O  Z 3 0)
O  Z  e t z c
4—1 Z  Z o rtj
Z  z  Z V) z E e t CM CO
e t CO in cn LO z
Z  Z  Z LO
=3 Z  Z Q Z e tz z z o
Q t
O  Z  Z CU
Z O O cn
fO
X  00 z z C
4—4 CD c
Z  00 e t <u E LO X CO
z  > - z u CO Z e tZ  z  Z Î - o
e t Z 0) CO
Z  Z :  CD z
O  eC OO
Z
LO Z  Z
Z  o
Z  —4 e t c
4—4 CO
Z  LO LO E CM CM zZ  e t LO e t CO
Z  OO LOo CD Q
LO
LO
X et
LO
LO
00
CM
LO
00
CO
COet
X
CO
LO
CMet XCO LOe t
LO
CO
e t
e t
CM
CO
CM
CO
X
CO
cn
CO
cn
CO
CM
CM
et
CM
X
CM
X
CO
Q . c
X o
z
zin (T3 CO
z t - “Oo c n  <u c
CU E oz Z  *p“ (D
eC c  z (UDC COz LOz
z £33
X— o O Z CO CO
e t cn z o z
X— CM X— CM X— X—
■acfO
c.
CO
4-3
c
CU
z
z
CU I
o c LOc c CD c c
o X oX s- X C o
o
CU
CU o o  z c n z
c CO E 3 3 03fO X 03 z T3 s-_1 _c CU Z 03 o zCU z JZ CO rC cc . > L c CO S- CU E CUOJ 03 CU Z cu &_ c to (D
s z O Q . o X T3 S- fO cCU (ICJ CO .o •o o o
z z s : O CQ CD o c_) 5^ CL CD
98
m
Lu
C OC3ea
f = 3
S
co
Figure iq
D isso lu tio n  ra tes  o f  the  seven types o f  d ig ox in
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digoxin concentrations. The data from the two groups verecombined by 
expressing mean concentrations as percentages of the mean concentration 
obtained with newer Lanoxin, which had been used by both groups, A 
good corre la tion  was found a t each of the dissolution te s t  time in terva ls  
(Table 13). The highest r value was at 30 minutes : r = 0.89 (p < 0 .0 1 ) .  
The re la tionsh ip  between the mean digoxin level and percentage of stated  
dose in solution is i l lu s t r a te d  in Figure 11,
The dissolution ra te  of the batch of Cox brand tab le ts  used in
the t r i a l  appeared to be much fa s te r  than the batch from the same
manufacturers reported in Table 7. The dissolution ra te  of the i n i t i a l  
batch had been measured by A.C, Caws a t the Burroughs Wellcome laboratory. 
To assess i f  these differences re flec ted  any influence from the 
methodology of the te s t ,  the f i r s t  batch of the Cox brand had its  
dissolution rate  measured by K. Raymond. The results are shown in 
Figure 12. Raymond also carried  out d issolution ra te  tests on a batch 
o f Lanoxin tab lets  manufactured p r io r  to the 1969 manufacturing 
m odification. The results of the three types of Lanoxin tab lets  are 
shown in Figure 13.
Thirteen patients in each group had a t r ia l  f i b r i l l a t i o n .  The 
v e n tr ic u la r  rates and plasma digoxin concentrations of the patients in 
group 1 are given in Table 15 and the results of the group 2 patients
are in Table 16. The results are summarised in Table 17, The differences
in ven tr ic u la r  rate in both groups were s t a t i s t ic a l ly  s ig n if ic a n t  
(analysis of variance, p < 0 . 0 1 ) .
No patient developed evidence o f d ig i t a l is  to x ic i ty .
In view o f the hypothesis from the e a r l ie r  experience that some 
patients were consistently more sensitive  to changes in ta b le t  brand 
than others, i t  was decided to examine i f  the data gathered in th is
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t r i a l  showed such a pattern . This was done in the following way.
Patients were divided into two sections - those who had (1) low or 
( 2 ) high plasma digoxin concentrations r e la t iv e  to th e ir  dose when 
using the brand of lowest b io a v a i la b i l i ty  in th e ir  group. 0.5ng/ml 
or less was taken to be low fo r  a dose of O.ZSmg/day and 1.0ng/ml or 
less was taken to be low fo r  0.5mg/day. Since renal impairment would 
increase the steady s ta te  digoxin level fo r  any given dose, patients  
with a blood urea above 40mg/100ml were excluded. The percentage 
increase in plasma digoxin concentration a f te r  changing from the brand 
o f lowest b io a v a i la b i l i ty  to newer Lanoxin was then calculated  
(Tables 18 and 19). Those who had low digoxin concentrations r e la t iv e  to 
dose on the brand o f leas t b io a v a i la b i l i t y  showed a mean increase of 
91,0% (S.D. 80,9%) when using newer Lanoxin, while patients with a 
high concentration showed a smaller increase of 28.5% (S.D. 27.3%).
This d ifference in increase was s t a t i s t ic a l ly  s ig n if ic a n t  (p = < 0 .05 ,  
unpaired t  t e s t ) .  This re s u lt  did not however prove tha t a true trend 
in s e n s i t iv i ty  ex isted , since random erro r  in the radioimmunoassay was 
bound to have played some part in determining whether the pa tien t was 
selected fo r  the 'low' or 'high' grouping, and these random errors would 
not necessarily be rep licated  a t assay of samples taken when the patien t  
used newer Lanoxin. To overcome th is  e f fe c t ,  the increase in digoxin  
concentration when changing from the second least b ioavail able brand to 
newer Lanoxin was also ca lcu la ted , but with the patients remaining in 
the same 'low' and 'h igh' groupings which had been made on the basis 
of the leas t availab le  brand resu lts . Those in the 'low' group now showed 
an increase o f 50.0% (S.D. 39.1%) while  patients in the 'high' group 
showed a smaller increase of 18.2% (S.D. 21.9%), This d ifference  did 
not reach s ta t is t ic a l  s ign ificance but the presence of the same trend
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supported the hypothesis that some patients were more sensitive  than 
others to change in the dissolution rate  of th e ir  digoxin tab le ts .
DISCUSSION
This t r i a l  confirmed tha t d i f fe r e n t  brands of digoxin ta b le t  
marketed in the United Kingdom produced s ig n if ic a n t  differences in  
steady state  plasma digoxin concentrations in cardiac pa tien ts . These 
differences existed despite each brand meeting the prevailing  
B rit is h  Pharmacopoeia (1968) requirements of digoxin content and 
dis in tegra tion  time. The d ifferences in plasma digoxin concentration  
correlated well with the d issolution ra te  of these brands despite  
various manufacturing processes and excip ient substances being used.
A strong corre la tion  ( r  = 0 .97) between dissolution rate  and 
steady state  plasma digoxin concentration was found by Johnson et a l . ,  
(1973) in a study o f 5 experimental batches of Lanoxin with d issolution  
rates ranging from 54 to 98% at 1 hour. A s im ila r  close corre la tion  was 
obtained with batches from 8 American pharmaceutical companies by 
Lindenbaum et a l . ,  (1973). By 1975, 21 studies had shown a re la tionsh ip  
between in v i t r o  dissolution rate  and digoxin b io a v a i la b i l i ty  
(Greenblatt et a l . ,  1976). A few reports appeared to show exceptions 
to th is  re la tionsh ip . Klink e t  a l . ,  (1974) found tha t a ta b le t  with  
the remarkably slow dissolution rate  o f 8% at 1 hour gave moderately 
high digoxin concentrations during the absorption phase and had an equal 
area-under-the-curve at 48 hours as a digoxin e l i x i r .  These authors 
admitted to anomalies with th e ir  digoxin radioimmunoassay and 
methodological problems may have influenced the results  o f th is  study. 
Y l i t a lo ,  Wilen and Lundell (1975) found s im ila r  steady state  plasma 
digoxin concentration with a ta b le t  o f 58% -  1 hour d issolution rate
I l l
and a digoxin solution. One brand studied by Reissell et a l . ,  (1977) 
appeared to have fa s t  d issolution in  v it ro  but poor absorption.
However the great weight of published (and unpublished) evidence 
pointed to a useful corre la tion  between in v itro  d issolution rate  
and digoxin ta b le t  b io a v a i la b i l i ty .
In addition to the variations in digoxin concentration, 
s ig n if ic a n t  differences were found in the resting ven tr ic u la r  rates 
o f the 26 patients with chronic a t r ia l  f ib r i l l a t i o n  (Tables 15, 16 
and 17). When th is  data was published (Shaw et a l . ,  1973) i t  was 
the f i r s t  study in the l i t e r a tu r e  on any drug to show correlations  
between dissolution ra te ,  plasma drug concentrations and therapeutic  
e f fe c t .  Improved control o f a t r ia l  f i b r i l l a t i o n  a f te r  a change in 
digoxin ta b le t  brand was also found by Redfors et a l . ,  (1973), Systolic  
time in terva ls  were noted to change with a lte ra t io n  in digoxin ta b le t  
brand (Fleckenstein et a l . ,  1974). Although those working to study 
digoxin b io a v a i la b i l i ty  t r ie d  to ensure that d ig i t a l is  to x ic i ty  was 
not provoked, a number of cases in c l in ic a l  practice were seen in 
which a change of brand provoked d ig i t a l is  to x ic i ty  (Redfors et a l . ,  
(1973), Shaw (1974)). An outbreak of digoxin to x ic i ty  was discovered 
at a hospital in Is rael a f te r  a local pharmaceutical company altered  
the b io a v a i la b i l i ty  o f i ts  digoxin tab lets  (Danon et a l . ,  1977).
Although the in v i t ro  dissolution rate te s t now c le a r ly  offered  
a prospect of ensuring consistent digoxin ta b le t  b io a v a i la b i l i t y ,  i t  
remained to establish what the l im its  for new pharmacopoeal standards 
of dissolution rate  should be.
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CHAPTER 5
BIOAVAILABILITY OF VERY RAPIDLY DISSOLVING 
DIGOXIN TABLET FORMULATION
INTRODUCTION
The close corre la tion  between in v i t ro  d issolution rate  and 
steady state  plasma digoxin concentrations indicated tha t th is  
te s t  would be a useful predictor o f  digoxin ta b le t  b io a v a i la b i l i ty .
When the steady state  concentration was plotted against dissolution  
rate  there was a suggestion tha t there might be a ra te  above which no 
fu rth er  increase in digoxin b io a v a i la b i l i ty  would occur (Lindenbaum 
et a l . ,  1973, Johnston e t a l . ,  1973, Shaw e t a l . ,  1973). I f  th is  
was the case th is  rate  could be used as a minimum dissolution rate  
requirement for pharmacopoeae to ensure equal b io a v a i la b i l i ty  fo r a l l  
brands of digoxin ta b le t .  To te s t  th is  hypothesis, 5 formulations, 
designed to provide very rapid d isso lu tio n , were obtained for assessment 
of th e ir  b io a v a i la b i l i ty .
Formulations producing rapid absorption of digoxin give high 
plasma digoxin concentrations during the absorptive phase. To 
investigate  i f  high peak concentrations during absorption might produce 
trans ient digoxin to x ic i ty  a group o f 8 cardiac patients had th e ir  
electrocardiogram recorded before and a f te r  a 0.5mg dose of digoxin 
solution .
METHODS
Formulations
The formulation studied were:-
1. Lanoxin (batch 1579X) o f the type produced and marketed since
the production th^ange of T972 -  i . e . st^rrdard ' newer' Lanoxin.
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2. An experimental batch o f Lanoxin containing the same excipients
as the standard Lanoxin formulation but modified to produce 
fas te r  d issolution.
3. A rapidly  dissolving brand of digoxin availab le  commercially
in Scandanavia -  Lanacrist tab lets  (batch YE 192) produced 
by the A.B. Draco company in Sweden.
4. A ta b le t  formulation o f digoxin prepared in the Department of
Pharmacy, Chelsea College, London. This was based on the 
methodology of Monkhouse and Lach (1972) whereby rapid 
dissolution of poorly soluble drugs is achieved by adsorbing 
them to an insoluble agent with an extensive surface, thereby 
increasing the e ffe c t iv e  surface area of the drug. In th is  
formulation the digoxin was adsorbed onto calcium carbonate 
(Mohamad, 1973).
5. An experimental batch o f digoxin ta b le t  produced by the N a tiv e l le  
company of France, containing micronised digoxin with a 50% 
p a rt ic le  size of 5.6pm.
A f lu id  preparation of digoxin (Lanoxin for in je c t io n , lo t  80601) 
was used in the assessments of ra te  of absorption.
Dissolution rates
Dissolution ra te  measurements o f these formulations were carried  
out separately in two laboratories using s l ig h t ly  d i f fe re n t  techniques. 
Dissolution rates measured at the Department of Pharmaceutics,
The School of Pharmacy, London were based on the 1970 United States 
Pharmacopoeia method (Raymond et a l . ,  1974), as described in Chapter 4.
Dissolution rates were also measured by Lars Nyberg in the 
Analytical Laboratory of the Research and Development Department of  
A.B. Draco of Lund, Sweden. Ten tablets  were placed in a basket
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ro ta ting  at 100 revolutions per minute in 900ml of simulated gastric  
f lu id  without pepsin at 37°C. 5m1 samples for f lu o r im etr ic  assay 
were taken at in terva ls  up to 2 hours. The method has been described 
in d e ta il  by Nyberg et a l . ,  (1974b).
Subjects
Absorption curves
Absorption curves were recorded in two groups of subjects.
A) Four normal ambulant subjects received, in randomised order, 0.5mg 
doses o f digoxin solution and formulations 1, 3 and 4. The dose 
was given with 40ml o f water a f te r  overnight fa s tin g . At leas t  
one week elapsed between administrations.
B) Four cardiac p a tie n ts , not normally receiving digoxin, who were 
free  of cardiac f a i lu r e  and in a stable cardiac state received 
O.Smg doses of digoxin solution and formulations 1 and 5 in a 
manner s im ila r  to that for f i r s t  group.
Steady state  plasma digoxin concentrations
Eleven cardiac out-patients  were given one week courses of  
formulations 1, 2 , 3, 4 and 5 with the order randomised. The dosage 
used was 0.25mg or O.Smg per day and was unaltered fo r  each indiv idual 
during the study. Other medications were not changed. The d a ily  
digoxin dose was taken each evening. The discrepancy in ta b le t  count 
was 1%. There was a period of a t  leas t 10 hours (mean 13.0 hours) 
between the la s t  dose and the blood sample taken at the end of each week's 
course of digoxin treatment. Ten o f the patients had a blood urea o f  
less than 40mg/100ml; one patien t had a blood urea of 45mg/100ml. The 
patients in this group had previously been found to have an increase in 
plasma digoxin concentration o f 40% when they changed from older to 
newer Lanoxin.
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Arrhythmia study group
Eight cardiac patients had lead I I  of th e ir  electrocardiogram  
recorded fo r  1 hour before and 6 hours a f te r  a 0.5mg dose of digoxin 
solution. Patients selected fo r  th is  group were on regular digoxin 
therapy and had v e n tr ic u la r  ectopy considered due to th e ir  heart 
disease and not to digoxin to x ic i ty .  Each had a steady state  plasma 
digoxin concentration of less than 2ng/ml. These patients fasted 
overnight p r io r  to the dose o f digoxin solution. They remained 
semi-supine in bed during the recording period. The characteris tics  
of these patients are included in Table 24. Their rhythm was recorded 
simultaneously on paper at 5mm/sec and on a tape recorder. The 
to ta l number of ven tr ic u la r  and supraventricular premature beats 
per 15 minute in terva l was counted. I f  the nature of the rhythm 
was unclear on the paper record, the corresponding portion was taken 
from the tape recording and re-played onto paper at a speed of 25 or 
50mm/sec. Blood samples fo r  plasma digoxin concentration were taken at  
30 minute in terva ls  up to 2 hours and then hourly up to 6 hours.
RESULTS
The dissolution rates o f the 5 ta b le t  formulations are given 
in Tables 20 and 21. The dissolution rate  p ro f i le s ,  as measured at  
the laboratory in Sweden, are i l lu s t ra te d  in Figure 14. A good 
correlation  existed between the dissolution rate results of the two 
laboratories; r = 0.97 (20 minutes), r  = 0.98 (30 minutes). The 
re la tionsh ip  between results from the two laboratories are shown 
in Figure 15. In the Swedish laboratory the d issolution rate tended
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to be consistently s l ig h t ly  higher than the resu lt  obtained fo r  
the same formulation in London. The mean amount in solution at  
30 minutes was 93% in Sweden and 84% in London.
The absorption curves found in the group A and B subjects 
are shown in Figures 16 and 17. The peak plasma digoxin concentrations 
and the time in te rva ls  from administration o f dose to peak 
concentration are given in Table 22. Formulations 1 , 3 , 4  and 5 were 
a l l  rap id ly  absorbed although peak levels were s l ig h t ly  less than 
those found a f te r  the dose of digoxin in solution. The normal subjects 
reported trans ient nausea at 1 -  2 hours a f te r  the dose in 6 of the 
16 administrations. The patients in group B said they had not 
experienced any nausea.
The plasma digoxin concentrations recorded in the 11 out-patients  
who took one week courses of each formulation are given in Table 23.
The mean plasma digoxin concentrations found with each brand were very 
sim ila r  and the very small d ifferences were not s t a t i s t ic a l ly  
s ig n if ic a n t  (p > 0 .05 , paired t  t e s t ) .
The to ta l numbers o f ectopic beats recorded per hour in the 
8 cardiac patients before and a f te r  the O.Smg dose of digoxin solution  
are shown in Table 24. The plasma digoxin concentrations recorded 
before the dose and the peak level a f te r  the dose are included in the 
ta b le . The mean peak level was 3.29ng/ml. Only pa tien t 6 had 
a trans ient increase in ectopic count immediately a f te r  the dose.
The frequency o f  ectopics in th is  patient was very variab le .
Inspection of the ectopic count at 15 minute in terva ls  showed there  
was not a consistent re la tionsh ip  between ectopic count and rise  of 
digoxin concentration. In no case was coupling or runs o f v e n tr icu la r  
ectopics seen to coincide with peak digoxin leve ls .
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recorded by the Analytical Laboratory, AB Draco. 
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Figure 15 Comparison of d issolution rate  results obtained
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TABLE 22
PEAK PLASMA DIGOXIN CONCENTRATIONS AND TIME INTERVALS BETWEEN 
DOSE AND PEAK CONCENTRATION IN THE ABSORPTION CURVES 
OF PATIENTS IN GROUPS A AND B
Formulation Peak plasma 
digoxin concentration  
(ng/m l)
Mean ± S.D.
Time in te rv a l to  
peak concentration  
(mi nutes)
Mean ± S.D.
A) Solution
1
3
4
4.25 ± 0.47 
2.75 ± 0.59 
3.35 ± 0.86 
3.10 ± 0.50
45 ± 30 
60 ± 35 
5 3 ± 29 
60 ± 0
B) Solution
1
5
3.70 ± 1.21 
2.73 ± 1.23 
3.05 ± 0.61
53 ± 15 
60 ± 24 
60 ± 24
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TABLE 23
STEADY STATE PLASMA DIGOXIN CONCENTRATIONS FOUND IN 
11 PATIENTS AFTER ONE WEEK COURSES OF FORMULATIONS 1 -  5
Formulation
Plasma digoxin concentration
________ (ng/ml_)_________ _
Mean S.D.
1 1.45 0.33
2 1.47 0.28
3 1.42 0.32
4 1.48 0.50
5 1.45 0.39
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DISCUSSION
There was a close corre la tion  between the dissolution rate  
results obtained in London and those obtained in Sweden, although 
the methods used d if fe re d  in several charac te r is tics . The 
methodology o f a dissolution rate  te s t  could a f fe c t  the re su lt  in  
a number of ways. These include the tendency to clogging of the 
mesh basket, the e f fe c t  of the l iq u id  medium on the tab le ts  and on the 
metal components o f the apparatus, and the mixing pattern produced 
by v ibration  and the shape o f the vessel (Raymond et a l . ,  1974).
Studies undertaken by the B r it is h  Pharmacopoeia Commission showed 
that in terlabo ra tory  differences in digoxin ta b le t  dissolution rate  
of reference formulations were not so large as to preclude the 
setting  o f dissolution ra te  c r i t e r ia  (unpublished data ).
Each of the ta b le t  formulations were found to have a rapid 
dissolution ra te . The slowest dissolving formulation was formulation 5 
which had a rate  o f 70% in solution at 30 minutes as measured in the 
London laboratory , and of 79% at 30 minutes, 85% at 60 minutes and 
91% at 120 minutes in the Swedish laboratory. As each o f the 
formulations produced s im ila r  steady state  plasma digoxin concentrations 
th is suggested that a d issolution rate  in the range 70 - 80% at 
30 minutes would be a su itab le  standard to ensure equal digoxin ta b le t  
b io a v a i la b i l i ty .
Johnson and Lader (1974) compared the b io a v a i la b i l i ty  of 
standard newer Lanoxin (d issolution rate  79% at 15 minutes and 98% 
at 60 minutes) with Lanoxin modified to produce very rapid dissolution  
and with capsules containing u l t ra - ra p id ly  dissolving digoxin (both 
released 100% of the dose in 7.5 minutes). They measured the areas 
under absorption curves of 80 hours duration and the urinary digoxin
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excretion over 10 days. They found no d ifference between these 
three formulations. Each had a b io a v a i la b i l i ty  equivalent to a digoxin  
solution . Greenblatt and Koch Weser (1974) found no d ifference in  
b io a v a i la b i l i ty  between tab le ts  o f d issolution rates 85% in 1 hour 
and 90 to 95% in 1 hour. Both provided absorption equivalent to a 
l iq u id  preparation of digoxin.
When the drug regulating agencies came to devise standards fo r  
digoxin b io a v a i la b i l i ty  they adopted d i f fe re n t  approaches. In B r ita in  
the f i r s t  step had been to advise th a t Lanoxin should be dispensed 
only when i t  had been specified by the prescriber (Lancet, 1972).
This followed the unexpected increase in Lanoxin b io a v a i la b i l i ty  and 
was designed to prevent an outbreak o f to x ic i ty .  The B rit ish  
Pharmacopoeia added an amendment (e f fe c t iv e  from 1st February 1973) 
to i ts  1968 Edition to establish l im its  on the content of individual  
digoxin ta b le ts ,  whereas previously content had been measured in a 
combined sample of 20 tab lets  (Pharmaceutical Journal, 1972b). This 
was based on published (Oudtshoorn (1972), Manninen and Korhonen (1973))  
and unpublished information that some brands of digoxin ta b le t  showed 
a very wide va r ia t io n  in the content of individual ta b le ts . This 
action probably removed some brands of low b io a v a i la b i l i ty  from the 
market since marked va ria t io n  in content re flec ts  poor mixing during 
ta b le tt in g  and th is  could be associated with low b io a v a i la b i l i ty  
(see Chapter 6 ) .  B r it ish  digoxin tab lets  now had to meet the 
following content requirements : 9 of 10 tablets  tested to be w ith in  
80 - 120% o f stated dose and a l l  w ith in  75 - 125%. In 1973 the 
Department of Health and Social Security undertook a review of a l l  
product licences issued to pharmaceutical companies in respect of 
digoxin ta b le ts  (Pharmaceutical Journal, 1973). The question of
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digoxin b io a v a i la b i l i ty  was reviewed by a Digoxin Tablets Panel 
o f the Medical Chemicals Committee o f the B rit ish  Pharmacopoeia 
Commission. From 1st October 1975, the Pharmacopoeia had an added 
amendment requiring a l l  digoxin tab le ts  marketed w ith in  the United 
Kingdom to have a d issolution ra te  o f not less than 75% of stated  
dose in solution at 1 hour.
Not a l l  countries adopted the same standard. In the Netherlands 
the d issolution rate  l im i t  was set a t 90% at 1 hour. The I t a l i a n  
Pharmacopoeia required a ra te  exceeding 70% at 30 minutes (Stewart 1981), 
In the United States the Food and Drug Administration had not had the 
problem o f a sudden change in the leading digoxin brand. They were 
faced however with products whose dissolution rate ranged from 3.8% to 
93.5% at 1 hour (H arter, S ke lly  and Steers, 1974). As a f i r s t  step 
they wished to e lim inate very poorly absorbed brands, but also to delay 
the marketing of very rap id ly  dissolving formulations u n ti l  the safety  
of rapid absorption had been re-assessed. Accordingly they set both 
lower and upper l im its  fo r  permitted dissolution rate  : 55% and 95% at 
1 hour. The former was soon afterwards raised to 65% (Harter et a l , ,
(1974), Harter (1 975 )) .  The digoxin dissolution ra te  method of the
U.S. Pharmacopoeia uses a series of s ingle  ta b le t  estimations whereas 
in the B r it is h  method a group of 6 tab le ts  are used. The FDA also 
required from each manufacturer in vivo b io a v a i la b i l i ty  data to show 
that in 12 subjects the area under the digoxin plasma concentration
curve from 0 - 5  hours a f te r  s ingle doses is at leas t 75% of the mean
of areas from a digoxin solution and a reference ta b le t  formulation with  
a dissolution rate o f 75% at 1 hour. This protocol has been c r it is e d  
as imprecise (Kramer e t a l . ,  1977, Wagner et a l . ,  1977).
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The fac t tha t the American standards encompass digoxin tab lets  
of incomplete re la t iv e  b io a v a i la b i l i ty  has been shown by studies 
which have compared U.S. Lanoxin with digoxin solution. Greenblatt 
et a l . ,  (1974) found 24% higher b io a v a i la b i l i ty  from tablets  of  
dissolution rate 85 - 90% at 1 hour compared with those of dissolution  
rate  64 - 65% at 1 hour. U.S. Lanoxin was less well absorbed than a 
digoxin solution in studies by Greenblatt e t a l . ,  (1973), Huffman et a l . ,  
(1974), and Lloyd et a l . ,  (1978), although Marcus et a l . ,  (1976) 
found equivalent b io a v a i la b i l i ty .  When the results o f these 4 studies 
are combined digoxin solution has an average b io a v a i la b i l i ty  of 67% 
re la t iv e  to an intravenous dose, and U.S. Lanoxin tablets  have a 
b io a v a i la b i l i ty  of 55%, From the biopharmaceutical point of view 
the submaximal absorption of American digoxin tab lets  represents a less 
than ideal s itu a t io n  since in te r -s u b jec t differences in absorption 
became more marked as dissolution rate  and absorption decrease (Levy 
and G iba ld i,  1974, Johnson et a l . ,  1976a, Johnson, Smith and French, 1977)
One report suggested that rapid absorption o f digoxin, and i ts  
associated higher plasma digoxin concentrations, might produce 
trans ien t d ig i t a l is  to x ic i ty  (Manninen, Reissell and Paukkala, 1976).
This study lacked a control period and did not accord with many 
unpublished observations of others or with the results in the cardiac 
patients reported in this Chapter. The patients reported here had 
a l l  shown a tendency to ectopic inpulse formulation but th is  did not 
show any tendency to increase along with the r is e  in digoxin 
concentration during the absorption phase, although plasma digoxin 
concentration rose well above 2ng/ml. No trans ien t arrhythmias were 
seen in a study o f cardiac paedia tric  cases (Larese and Mirkin (1974)).  
These findings r e f le c t  the  fa c t  tha t absorption phase plasma digoxin 
concentrations are not id en tica l to digoxin receptor concentration.
I j u
Nausea was reported in 6 o f 16 administrations o f  the 0.5mg 
dose by the normal subjects in group A (each o f whom was a hospital 
pharmacist) but no nausea was reported in group B. Nausea had not 
been reported when the ou t-p a tien t survey patients were changed 
to newer Lanoxin, although each patient had been questioned about 
symptoms o f possible to x ic i ty .  The basis for the high incidence o f  
early  and tran s ien t nausea in group A is not c le a r . In my own 
experience with rap id ly  dissolving tab le ts  in c l in ic a l  practice  
gastr ic  intolerance of digoxin is seen very occasionally, but is 
probably more frequent than had been the case with slowly dissolving  
formulations.
The digoxin b io a v a i la b i l i ty  studies o f the 1970's acted as a 
reminder that the absorption o f oral d igoxin, even as a so lu tion , was 
incomplete. Three approaches were used in attempts to find  an 
improvement on th is  s itu a t io n . The other natura lly -occurring cardiac 
glycosides were re-assessed, new types of digoxin formulation were 
developed, and semi-synthetic derivatives of digoxin were evaluated.
D ig itoxin  is more l ip o p h i l ic  than digoxin and had appeared 
to be completely absorbed in the studies by Gold et a l . ,  (1953) and 
Weissler et a l . ,  (1966). V ir tu a l ly  complete absorption from solution  
and rap id ly  dissolving tab lets  o f d ig itox in  was confirmed in more recent 
work (Beermam, Hel1 Strom and Rosen (1971), Vohringer, Wogenstein and 
Rietbrock (1977), Vohringer, Leopold and Rietbrock (1977), Greeff et a l . ,  
(1977), Greeff et a l . ,  (1979), S torste in  and Johsgard (1981)). S to ll  
et a l . ,  (1973) had found s im ila r  b io a v a i la b i l i ty  with two commercial 
brands of d ig ito x in  ta b le ts ,  one having a d issolution rate  o f 95% 
at 15 minutes and the other 65% at 60 minutes. However, Wood e t a l . ,  (1975) 
Ta te r  stated that d ig i tox in  t i  o a w i Tati T ity  showed "a x  Tear dependency"
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on dissolution ra te . This b r ie f  report did not include any data. Much 
o f the information on d ig ito x in  ta b le t  characteris tics  appears to have 
remained unpublished in FDA f i l e s .  The FDA Drug B u lle tin  (1976) did 
report tha t in the FDA tests of commercial d ig ito x in  tablets  some had 
shown "absorption as low as 60%”. The magnitude o f va r ia t io n  between 
brands was less than the FDA had found in tests of digoxin tab le ts  
(where they had found some brands had a to ta l absorption ”as low as 
10 - 15%"), however approximately 50% of digi toxin brands had to be 
reformulated when the dissolution rate  c r i t e r ia  was raised to not less 
than 50% at 30 minutes and not less than 85% at 1 hour. A real but less 
publicised b io a v a i la b i l i ty  problem did therefore ex is t  with d ig ito x in .
The FDA also stated th a t i t  had proved possible to manufacture d ig ito x in  
tab lets  of "100% b io a v a i la b i l i ty " .  However in te r -su b jec t varia tion  in 
steady state  plasma concentration and pharmacologic e f fe c t  is as great 
with d ig ito x in  as with digoxin (Belz e t a l . ,  1978), re f le c t in g  the 
importance of other pharmacokinetic and physiological factors .
In 1981 Sandoz Products Ltd. announced that a reformulation of 
th e ir  lanatoside C (Cedilanid) tab le ts  had given "greater b io a v a i la b i l i ty " .  
Some novel digoxin formulations appeared. A digoxin in e r t  c a rr ie r  
prec ip ita te  (a concept s im ila r  to formulation 4) was assessed in v i t ro  
and gave rapid dissolution rates (Reddy, Khalil and Gouda (1976)) .
Bochner e t a l . ,  (1977) developed a digoxin-hydroquinone complex 
formulation which gave 99% dissolution at 5 minutes. However, no 
greater absorption was found than with conventional tab lets  of  
dissolution rate 74% at 30 minutes and 88% at 60 minutes. The greatest 
in te re s t  was shown in a special l iq u id  digoxin preparation which was 
encased in a so ft g e la tin  capsule. The digoxin was dissolved in a 
polyethylene glycol-ethanol solution and t h i s , rather than the encapsuTation 
appeared to have an influence on absorption (O'Grady et a l . ,  1978).
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A number of investigators reported on th is  type o f formulation - 
M allis  et a l . ,  (1975), Johnson et a l . ,  (1976a), Binnion (1976),
Marcus et a l . ,  (1976), Lindenbaum (1977) and Lloyd et a l . ,  (1978). 
Overall in these studies there was a mean increase o f 17% in 
absorption r e la t iv e  to solution when absorption was assessed by 
the area-under-the-curve method, and of 12% when absorptions were 
compared using cumulative urinary excretion. Absolute b io a v a i la b i l i ty  
was s t i l l  sub-maximal, averaging 83% when results o f the plasma and 
urinary indices were combined. Most of these studies did not show 
a s ig n if ic a n t  decrease in in te r -s u b je c t  v a r i a b i l i t y ,  except when 
comparison was with U.S. Lanoxin tab lets  rather than solution.
Rodgers et a l . ,  (1977) did not find any improvement in c l in ic a l  e f fe c t  
when capsules were used instead o f B r it is h  newer Lanoxin ta b le ts .  
Considerations o f cost-effectiveness appear to have in h ib ited  these 
newer formulations from achieving commercial production.
Methyl digoxin is  a semi-synthetic der iva tive  o f digoxin which 
has a methyl group attached to the terminal sugar, giving i t  greater 
water and l ip id  s o lu b i l i ty  than digoxin and resu lting  in greater 
hepatic metabolism. Single dose studies (Boerner et a l . ,  (1976),  
Rietbrock et a l . ,  (1976), Hinderling et a l . ,  (1977)) indicated that  
methyl digoxin had a high but s t i l l  incomplete b io a v a i la b i l i ty .
Greeff et a l . ,  (1977) found i t  to be only s l ig h t ly  be tte r  absorbed 
than digoxin. S im ilar results  have been obtained with acetyl digoxin. 
The s lig h t  improvement in absorption does not seem to have outweighed 
the greater f a m i l ia r i t y  which c lin ic ia n s  have with digoxin, and digoxin  
remained the most commonly prescribed cardiac glycoside.
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CHAPTER 6
THE EFFECT OF PARTICLE SIZE ON THE ABSORPTION OF DIGOXIN
INTRODUCTION
While the dissolution ra te  te s t  offered an e f fe c t iv e  method 
for ensuring equivalent digoxin ta b le t  formations from d i f fe re n t  
manufacturers, i t  was important fo r  those producing digoxin tab lets  
to be aware of the parameters which determined digoxin b io a v a i la b i l i ty .  
Only in th is  way could they design th e ir  production process with  
confidence and prevent minor a lte ra t io n s  in technique from a lte r in g  
batch to batch consistency.
A fte r  discussions with many pharmaceutical companies, I could 
not f ind  any excipient substance which would explain differences in  
dissolution. All of the B rit is h  companies who made digoxin tab lets  
began with powder of pure digoxin supplied from one o f three sources -  
Burroughs Wellcome Ltd, Wander Ltd and the N ative !le  company of France - 
and yet ended with formulations of very d if fe r in g  dissolution rates .  
When a drug is poorly soluble in water the major determinant of i ts  
release into so lu tion , given a ra p id .ta b le t  d is in tegra tion  ra te ,  is 
the p a r t ic le  size of the drug in the ta b le t .  A change in p a r t ic le  size  
as the explanation fo r  a lte ra t io n s  in digoxin b io a v a i la b i l i ty  f i t t e d  
with the early  observation that grinding a poorly absorbed ta b le t  into  
a f in e  powder increased absorption. This concept was also supported 
by the knowledge that manufacturers used d i f fe re n t  t r i tu r a t io n  and 
grinding times in th e ir  ta b le t t in g  process, and th is stage of  
ta b le tt in g  is known to be able to a l t e r  p a r t ic le  size (Cooper and 
Rees, 1972).
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A d i f f i c u l t y  in tes ting  the hypothesis that p a r t ic le  size  
influenced digoxin absorption was that i f  a powder of known 
p a r t ic le  size was made in to  a ta b le t  in the normal way, the f in a l  
p a r t ic le  size became unknown. I t  was decided to circumvent th is  
problem by using cachets to enclose digoxin powders of known p a r t ic le  
size . I t  was decided to study the absorption obtained with the 
unmodified digoxin powder as supplied to pharmaceutical companies and 
then to study how reduction in the p a r t ic le  size o f th is  powder 
influenced absorption.
METHODS
Digoxin powders
Three digoxin powders used commercially in the United Kingdom 
for  digoxin ta b le t  production were obtained for measurement o f p a r t ic le  
size . These powders were from (1) Burrough Wellcome Ltd, batch 3608,
(2) Laboratoire N a t iv e l le  (P a r is ) ,  batch 4500 V I I I  1972 and (3) Wander Ltd 
(a B r it is h  d is tr ib u to r  of Sandoz), batch 10702.
To produce a powder of smaller p a r t ic le  size a 250mg portion of  
the Burrough Wellcome powder was m illed  in  a Glen Greston M270 agate 
vibra tory  ball m ill  for 15 minutes.
A second portion of the same powder was s im ila r ly  m illed fo r  
45 minutes. With th is  duration of m il l in g  i t  was found necessary to 
add as lubricant 2% Aerosol 200 (Degussa) to prevent caking of the 
powder.
Melting point behaviour of the digoxin, recorded with a Perkin 
Elmer D if fe re n t ia l  Scanning Calorimeter, did not a l te r  a f te r  the 
15 or 45 minute m i l l in g ,  suggesting that the m ill in g  had not a ltered  
the digoxin c ry s ta l l in e  form.
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Measurement o f  p a r t ic le  size
The p a r t ic le  sizes o f the Burroughs Wellcome, N a t iv e l le  and 
Wander powders were determined with a photoextinction sedimentometer 
(Evans Electroselenium L td ). The powder was suspended in water 
which contained a non-ionic wetting agent and was dispersed by 
ag ita tio n  in an ultrasonic bath. P a r t ic le  size d is tr ib u t io n  was 
calculated by the method of Edmundson (1967).
P a r t ic le  size of the ba ll m illed samples was measured by 
Coulter Counter (Model B : Coulter Electronics In c . )  f i t t e d  with  
a 100pm o r i f ic e  tube. The digoxin was suspended in 0.9% NaCl 
solution containing a non-ionic wetting agent in an ultrasonic  bath. 
Preparation of cachets
Sets o f r ice  paper cachets containing the unmilled Burroughs 
Wellcome powder, the 15 minute m illed powder and the 45 minute m illed  
powder were prepared. Each type of powder was f i r s t  mixed by 
t r i tu r a t io n  with lactose in a small mortar. The t r i tu r a t io n  process 
was standardised to avoid fu rth er  reduction of digoxin p a r t ic le  s ize .
Each cachet contained 0.25mg or 0.5mg digoxin and lactose to a to ta l  
weight of 200mg. Digoxin content of individual cachets was measured 
and did not exceed ±15% o f nominal dose.
The measurement of p a r t ic le  s ize and preparation of the cachets 
were carried out by Professor J.E. Carl ess of the Department of Pharmacy, 
Chelsea College, London.
Cachet dissolution rate  tests
The cachets were examined by K. Raymond with the in v i t ro  dissolution  
ra te  te s t  apparatus described in chapter 4. Single cachets were used.
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Patients  
Group A
The rate o f digoxin absorption from the unmilled Burroughs 
Wellcome powder and the 45 minute m illed powder were compared with  
that from a digoxin solution (Lanoxin fo r in je c tio n ) in 4 normal 
ambulant subjects. A single cachet o f O.Smg digoxin was taken with  
40ml water a f te r  an overnight fa s t .  The order o f administration was 
randomised. There was a one week in terva l between doses. Plasma 
digoxin concentrations were recorded for 6 hours a f te r  the dose.
Group B
The unmilled powder was also compared with the 15 minute milled  
powder in 4 ambulant cardiac patients who were on regular digoxin 
treatment. A O.Smg digoxin cachet was administered in place of the 
patients ' normal ta b le t  dose. The patients had fasted overnight.
Blood samples were taken before the dose and for 3 hours a f te r .
Group C
The unmilled powder was compared with the 45 minute milled  
powder in a second group o f 4 patients in the same manner to that used 
with group B.
Group D
The extent o f digoxin absorption from each type of cachet was 
assessed by measurement of steady state  plasma digoxin concentrations 
in 9 cardiac ou t-patien ts . The unmilled and the 15 minute milled  
powders were given in randomised order. The 45 minute m illed powder 
cachets became ava ilab le  la te r  and were administered 2 - 4  weeks 
a f te r  the f i r s t  two sets of cachets. Digoxin dosage was kept constant 
and other medication was not changed. A blood sample for plasma 
'digoxin xoncentratton estimation was taken a f te r  one week of treatment
of each type of cachet. The sample was taken 6 - 1 2  hours a f te r  
the la s t  dose, with the in terva l kept constant fo r  each in d iv id u a l.
The personal characteris tics  of these patients are included in Table 28,
RESULTS
The p a r t ic le  diameters o f the Burroughs Wellcome, N a t iv e l le  and 
Wander powders were found, in each instance, to be d is tr ib u ted  in a 
log-normal fashion i . e .  there was a normal (b e l l )  shape of d is tr ib u t io n  
when p a r t ic le  diameter was plotted on a logarithmic scale. With th is  
type o f d is tr ib u t io n  the arithm etic  mean is not appropriate and is  
replaced by ca lcu lation  of the "50% size" i . e .  the diameter size  
above and below which 50% of the measured diameters are d is tr ib u ted .
The 50% sizes of the 3 commercial digoxin powders are given in Table 25, 
The geometric standard deviations and the surface areas of the powders 
were calculated from the lo g -p ro b a b il i ty  plots of p a r t ic le  diameter 
(Thornton,1959, Edmundson, 1967) and are given in Table 25. The 
Burroughs Wellcome and N a t iv e l le  powders had a very s im ila r  pattern  
of p a r t ic le  s ize . The sizes in the Wander powder were s l ig h t ly  
la rger . The N a tiv e l le  powder had a surface area 39% la rger than that  
of the Wander powder.
B a l l -m il l in g  o f the Burroughs Wellcome powder did not a l te r  the . 
log-normal d is tr ib u t io n  pattern . The 50% sizes and surface areas of  
the m illed powders are included in Table 25. The d is tr ib u t io n  of 
p a r t ic le  sizes are shown on a lo g -p ro b a b ility  plot of p a r t ic le  
diameter in Figure 18. The 50% size of the 45 minute m illed powder 
has to be regarded as approximate and as an overestimate o f the true  
p a r t ic le  size as the d is tr ib u t io n  of sizes of this powder would suggest 
th a t a number o f partic les  would be below the l im i t  o f detection ( 2pm) 
of the measurement technique.
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Figure 18 Log-probability  p lo t of p a r t ic le  size o f
Burroughs Wellcome digoxin powder before and 
a f te r  b a l l -m i l l in g .
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The absorption curves of digoxin from the unmilled Burroughs 
Wellcome powder, from the 45 minute m illed powder and from the digoxin 
solu tion , as recorded in group A, are i l lu s t ra te d  in Figure 19. The 
peak plasma digoxin concentrations and the times to the peak are 
given in Table 26, The peak concentrations found with the 45 minute 
m illed powder were s ig n if ic a n t ly  higher than those recorded a f te r  the 
unmilled dose (P < 0 .05 , paired t  t e s t ) .  Both cachet formulations were 
more slowly absorbed than the solu tion .
The absorption curves recorded in the groups B and C are shown
in Figure 20. The peak r is e  in digoxin level and the times to the peak 
r is e  are given in Table 27. Administration of both m illed powders 
showed a fa s te r  absorption p ro f i le  than was recorded a f te r  the unmilled
powder dose. With the 45 minute m illed  powder peak digoxin concentrations 
were higher and e a r l ie r  than those a f te r  the 15 minute m illed  powder 
in the other group.
Plasma digoxin concentrations found in the patients of group D 
at the end of each week's treatment with cachets of unmilled powder,
15 minute milled powder, and 45 minute m illed powder are given in 
Table 28 and are shown in Figure 21. Patient 3 developed persistent  
nausea on the s ix th  day of treatment with the 45 minute m illed powder 
cachets: she omitted her la s t  dose and a plasma digoxin concentration 
on th is  formulation was not recorded. With th is  case excluded there  
was a 31% r is e  in mean steady state digoxin concentration from 
0.80 S.D. 0 .21ng/ml to 1.05 S.D. 0.35ng/ml between use of powders of 
22pm (unmilled) and 3,7pm (45 minute m illed ) p a r t ic le  s ize , (p < 0 .01 ,  
paired t  t e s t ) .  I f  a digoxin level of 2ng/ml is assumed fo r  pa tien t 3 ,  
the increase in digoxin level was 45%.
The amounts o f  digoxin in soTution a t 60 minutes tn  t:he tm v it ro  
dissolution rate tests were: unmilled 9%, 15 minute milled 18%;
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Figure 19 Absorption curves recorded in 4 normal subjects 
(Group A) a f te r  O.Smg digoxin doses administered 
as unmilled digoxin powder in a cachet (closed 
c ir c le s ) ,  45 minute m illed digoxin powder in a 
cachet (open c irc le s )  and a solution of digoxin 
(crosses).
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TABLE 26
PEAK PLASMA DIGOXIN CONCENTRATIONS (PDC) IN ng/ml 
AND TIME TO PEAK CONCENTRATION IN 4 NORMAL SUBJECTS 
AFTER O.Smg DOSES OF DIGOXIN POWDER 
IN CACHETS AND AFTER O.Smg OF DIGOXIN SOLUTION
Time (hours) to 
Formulation Peak PDC peak PDC
Mean ± S.D. Mean ± S.D.
(range) (range)
Unmilled 0.93 ± 0.05 1.63 ± 0 .2 5
powder (cachet) (0 .9  - 1.0) (1.5 -  2 .0 )
45 minute
m illed 1.93 ± 0.53 1.00 ± 0.41
powder (cachet) (0 .9  -  2 .1 ) (0.5 -  1 .5)
solution 3,25 ± 1 . 5 9  0.75 ± 0.29
(2 .0  -  5 .4 )  (0 .5  -  1 .0)
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Figure 20 Absorption curves recorded in Group B ( l e f t  hand panel) 
and Group C ( r ig h t  hand panel). Group B received O.Smg 
doses o f unmilled powder (closed c irc le s )  and 15 minute 
m illed  powder (open c ir c le s ) .  Group C received O.Smg 
doses o f unmilled powder (closed c irc le s )  and 45 minute 
m illed powder (open c i r c le s ) .
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TABLE 27
PEAK RISE IN PLASMA DIGOXIN CONCENTRATIONS (PDC) 
AND TIME TO PEAK RISE IN GROUPS B ANC C 
AFTER O.Smg DOSES OF DIGOXIN POWDER FORMULATIONS
Peak r is e  (ng/ml) Time (hours)
Group Formulation in PDC to peak PDC
+ g Mean ± S.D.
(range) (range)
Unmilled powder 1.27 ± 0.59 1.87 ± 0.85
(0 .8  -  2 .1 ) (1 .0  - 3 .0)
15 minute 2.00 ± 0.93 1.38 ± 0.25
milled powder (1.1 -  3 ,3 ) (1 .0  - 1 . 5 )
Unmilled powder 1.10 ± 0.28 1.88 ± 0.85
(0 .7  -  1 .3) (1 .0  -  3 .0 )
45 minute 2.98 ± 1.14 1.13 ± 0.25
m illed powder (1 .6  -  4 .4 )  (1 .0  -  1 .5)
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Figure 21 Steady state  plasma digoxin concentrations recorded 
in 9 out-patients a f t e r  each weeks' treatment with 
cachets containing digoxin powder o f  d i f fe r in g  
p a r t ic le  size.
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45 minute milled 25% (Figure 22).  The cachets did not d isintegrate  
although they did become permeated with water (Figure 23).
DISCUSSION
These results showed that  the 3 commercially-avai1 able digoxin 
powders used fo r  digoxin ta b le t t in g  in the United Kingdom a l l  had 
pa r t ic le  diameters whose 50% size was in the range 20 - 30pm. When 
the unmilled Burroughs Wellcome powder was mixed with only lactose and 
administered within  a cachet the absorption of digoxin was slower 
and less complete than that  obtained with powders mil led to give 
p a r t ic le  sizes of 12 and 3.7pm.
In v i t ro  dissolution rate also increased as p a r t ic le  size 
reduced. The ranking in th is  tes t  would be va l id  but the absolute 
values of  dissolution rate must have been affected by the lack of 
disintegrat ion of  the cachet walls . This would prevent c ircu la t ion  
of the water within the cachet. The e f fec t  of p a r t ic le  size on the
dissolut ion rate  of digoxin powders was also demonstrated by
Florence, Salole and Stenlake (1974) who also found evidence to 
suggest that  dry grinding altered the proportion of  amorphous and 
c ry s ta l l in e  forms. Johnson, O'Grady and Bye (1978) obtained a
dissolut ion rate of  100%. at 7.5 minutes with tablets containing
digoxin of p a r t ic le  size "under 10pm" and a rate of 34% at 1 hour 
with tablets of  digoxin of p a r t ic le  size "90 - 106pm".
Other workers have confirmed the important influence of  
p a r t ic le  size on digoxin absorption. Jounela, Pentikainen and 
Sothman (1975) recorded area-under-the-curve and urinary digoxin 
excretion indices at  steady state in 7 subjects. Tablets of digoxin 
of mean diameters (s ic )  13 and 7pm gave equivalent absorption to
1 4 W
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T I M E  ( M I N U T E S )
Figure 22 Dissolution rate prof i les  of  cachets containing
unmilled digoxin powder (closed c i r c le s ) ,  15 minute 
milled powder (open c i rc le s )  and 45 minute mil led  
powder (crosses).
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Figure 23 Appearance of a capsule in the basket at  the end of 
the dissolut ion rate tes t .
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digoxin solution while table ts  with digoxin part ic les  of 102pm 
gave less than half  th is absorption. Dissolution rate  increased 
as p a r t ic le  size reduced. Beveridge et a l . ,  (1975) noted reduced 
absorption from capsules containing "coarse par t ic les"  of digoxin.
In the study of Johnson, O'Grady and Bye (1978) cited e a r l i e r  the 
four day urinary digoxin excretion a f te r  single doses with tablets  
of large p a r t ic le  digoxin was ju s t  under ha l f  that  a f t e r  standard 
Lanoxin.
The Tog-normal d is t r ib u t io n  of digoxin p a r t ic le  diameters 
is consistent with the shape of  the curves obtained in tab le t  
dissolution rate  tests (Brooke 1978), which show the rate  of  release  
into solution progressively f a l l i n g  over several hours (Fraser  
et a l . ,  1974). The 50% of the part ic les  in the lower end of the 
log-normal size d is t r ib u t io n  are grouped into a narrower range 
of p a r t ic le  diameters and, in addit ion, since volume and mass 
increase with cube of the radius a greater  proportion of the dose 
is contained in a single large p a r t ic le  than in a single small 
p a r t ic le .
The finding that  the digoxin powders used by B r i t ish  digoxin 
ta b le t  manufacturers had a r e la t iv e ly  large p a r t ic le  size which 
gave poor digoxin absorption suggests that the m i l l ing  processes in 
production were c r i t i c a l  in determining the b io a v a i la b i l i t y  of the 
f in a l  product.
Par t ic le  size had been known in the 1960's to be an important 
determinant for  dissolut ion rate  and absorption of several poorly 
soluble drugs, such as gr iseofulv in  and chloramphenicol. - In  view of  
the promptings which had been given by academic pharmacists such as 
levy  m d  Nelson (T961) and Wagner (T971 ) i t  is disappointing that
i t  was only a f te r  the discovery o f  variable  digoxin absorption in 
c l in ic a l  studies that the pharmaceutical companies became aware of  
the digoxin b io a v a i la b i l i t y  problem.
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